<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1115" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1115/" /><meta name="ncbi_pagename" content="ATP1A3-Related Neurologic Disorders - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>ATP1A3-Related Neurologic Disorders - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="ATP1A3-Related Neurologic Disorders" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2018/02/22" /><meta name="citation_author" content="Allison Brashear" /><meta name="citation_author" content="Kathleen J Sweadner" /><meta name="citation_author" content="Jared F Cook" /><meta name="citation_author" content="Kathryn J Swoboda" /><meta name="citation_author" content="Laurie Ozelius" /><meta name="citation_pmid" content="20301294" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1115/" /><meta name="citation_keywords" content="Alternating Hemiplegia of Childhood (AHC)" /><meta name="citation_keywords" content="Cerebellar Ataxia, Areflexia, Pes Cavus, Optic Atrophy, and Sensorineural Hearing Loss (CAPOS) Syndrome" /><meta name="citation_keywords" content="Rapid-Onset Dystonia-Parkinsonism (RDP)" /><meta name="citation_keywords" content="Sodium/potassium-transporting ATPase subunit alpha-3" /><meta name="citation_keywords" content="ATP1A3" /><meta name="citation_keywords" content="ATP1A3-Related Neurologic Disorders" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="ATP1A3-Related Neurologic Disorders" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Allison Brashear" /><meta name="DC.Contributor" content="Kathleen J Sweadner" /><meta name="DC.Contributor" content="Jared F Cook" /><meta name="DC.Contributor" content="Kathryn J Swoboda" /><meta name="DC.Contributor" content="Laurie Ozelius" /><meta name="DC.Date" content="2018/02/22" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1115/" /><meta name="description" content="ATP1A3-related neurologic disorders represent a clinical continuum in which at least three distinct phenotypes have been delineated: rapid-onset dystonia-parkinsonism (RDP); alternating hemiplegia of childhood (ACH); and cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss (CAPOS). However, some affected individuals have intermediate phenotypes or only a few features that do not fit well into one of these major phenotypes." /><meta name="og:title" content="ATP1A3-Related Neurologic Disorders" /><meta name="og:type" content="book" /><meta name="og:description" content="ATP1A3-related neurologic disorders represent a clinical continuum in which at least three distinct phenotypes have been delineated: rapid-onset dystonia-parkinsonism (RDP); alternating hemiplegia of childhood (ACH); and cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss (CAPOS). However, some affected individuals have intermediate phenotypes or only a few features that do not fit well into one of these major phenotypes." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1115/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/rapid-odp/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1115/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8A91FEE03F0E510000000009EC0393.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1115_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1115_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/asah1/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/cutis-laxa/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1115_"><span class="title" itemprop="name"><i>ATP1A3-</i>Related Neurologic Disorders</span></h1><p class="contrib-group"><span itemprop="author">Allison Brashear</span>, MD, <span itemprop="author">Kathleen J Sweadner</span>, PhD, <span itemprop="author">Jared F Cook</span>, MA, <span itemprop="author">Kathryn J Swoboda</span>, MD, and <span itemprop="author">Laurie Ozelius</span>, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1115_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1115_ai__"><div class="contrib half_rhythm"><span itemprop="author">Allison Brashear</span>, MD<div class="affiliation small">Professor and Chair, Department of Neurology<br />Wake Forest School of Medicine<br />Winston-Salem, North Carolina<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.htlaehekaw@aehsarba" class="oemail">ude.htlaehekaw@aehsarba</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Kathleen J Sweadner</span>, PhD<div class="affiliation small">Associate Professor of Cellular and Molecular Physiology, Department of Surgery<br />Massachusetts General Hospital<br />Boston, Massachusetts<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.dravrah.hgm.xileh@rendaews" class="oemail">ude.dravrah.hgm.xileh@rendaews</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Jared F Cook</span>, MA<div class="affiliation small">Project Manager, Department of Neurology<br />Wake Forest University School of Medicine<br />Winston-Salem, North Carolina<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.htlaehekaw@koocraj" class="oemail">ude.htlaehekaw@koocraj</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Kathryn J Swoboda</span>, MD<div class="affiliation small">Director, Neurogenetics Unit<br />Center for Genomic Medicine<br />Department of Neurology<br />Massachusetts General Hospital<br />Boston, Massachusetts<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.dravrah.hgm@adobowsk" class="oemail">ude.dravrah.hgm@adobowsk</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Laurie Ozelius</span>, PhD<div class="affiliation small">Associate Neuroscientist, Department of Neurology<br />Massachusetts General Hospital<br />Boston, Massachusetts<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.srentrap@suilezol" class="oemail">gro.srentrap@suilezol</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">February 7, 2008</span>; Last Update: <span itemprop="dateModified">February 22, 2018</span>.</p><p><em>Estimated reading time: 34 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="rapid-odp.Summary" itemprop="description"><h2 id="_rapid-odp_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p><i>ATP1A3</i>-related neurologic disorders represent a clinical continuum in which at least three distinct phenotypes have been delineated: rapid-onset dystonia-parkinsonism (RDP); alternating hemiplegia of childhood (ACH); and cerebellar ataxia, areflexia, <i>pes cavus</i>, optic atrophy, and sensorineural hearing loss (CAPOS). However, some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have intermediate phenotypes or only a few features that do not fit well into one of these major phenotypes.</p><ul><li class="half_rhythm"><div>RDP has been characterized by: abrupt onset of dystonia over days to weeks with parkinsonism (primarily bradykinesia and postural instability); common bulbar involvement; and absence or minimal response to an adequate trial of L-dopa therapy, with few exceptions. Often fever, physiologic stress, or alcoholic binges trigger the onset of symptoms. After their initial appearance, symptoms often stabilize with little improvement; occasionally second episodes occur with abrupt worsening of symptoms. Rarely, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have reported a more gradual onset of symptoms over weeks to months. Anxiety, depression, and seizures have been reported. Age of onset ranges from four to 55 years, although a childhood variation of RDP with onset between ages nine and 14 months has been reported.</div></li><li class="half_rhythm"><div>AHC is a complex neurodevelopmental syndrome most frequently manifesting in infancy or early childhood with paroxysmal episodic neurologic dysfunction including alternating hemiparesis or dystonia, quadriparesis, seizure-like episodes, and oculomotor abnormalities. Episodes can last for minutes, hours, days, or even weeks. Remission of symptoms occurs with sleep and immediately after awakening. Over time, persistent neurologic deficits including oculomotor apraxia, ataxia, choreoathetosis, dystonia, parkinsonism, and cognitive and behavioral dysfunction develop in the majority of those <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>; more than 50% develop epilepsy in addition to their episodic movement disorder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</div></li><li class="half_rhythm"><div>CAPOS (<i>c</i>erebellar ataxia, <i>a</i>reflexia, <i>pes cavus</i>, <i>o</i>ptic atrophy, and <i>s</i>ensorineural hearing loss) syndrome is characterized by episodes of ataxic encephalopathy and/or weakness during and after a febrile illness. Onset is between ages six months and four years. Some acute symptoms resolve; progression of sensory losses and severity vary.</div></li></ul></div><div><h4 class="inline">Diagnosis/testing.</h4><p>Diagnosis of an <i>ATP1A3</i>-related neurologic disorder is established in an individual with the clinical features of RDP, AHC, or CAPOS syndrome and/or by the identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>ATP1A3.</i></p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Standard treatment of visual disturbance, hearing loss, seizure disorders, cardiac arrhythmia, and cardiomyopathy. Consideration of CPAP or BiPAP for those with sleep apnea. Those with severe dysphagia may require a gastrostomy tube. Physical therapy, occupational therapy, and speech therapy for motor dysfunction, ataxia, and dysarthria. Acute spasms may respond to chloral hydrate or other medication that induces sleep. Dystonia can be treated with benzodiazepines, dopamine agonists, or levo-dopa. Psychotherapy and standard pharmacotherapy for those with mood disorder or psychosis. Early referral for developmental support / special education.</p><p><i>Prevention of primary manifestations</i>: Prophylaxis for AHC episodes may include flunarizine, topiramate, a ketogenic diet, and sleep. A trial of high-dose benzodiazepines may be considered in individuals with RDP and AHC. Triggers that lead to acute attacks should be avoided.</p><p><i>Prevention of secondary complications</i>: When dystonia is present, physical therapy to prevent contractures in the hands and feet.</p><p><i>Surveillance.</i> Affected individuals should be monitored for the development of dysphagia (RDP and CAPOS syndrome), seizures (RDP and AHC), and psychiatric symptoms (RDP).</p><p><i>Agents/circumstances to avoid:</i></p><ul><li class="half_rhythm"><div>RDP. Triggers including alcohol, fever, psychological stress (e.g., childbirth), excessive exercise.</div></li><li class="half_rhythm"><div>AHC. Triggers including psychological stress / excitement; environmental stressors (e.g., bright light, excessive heat or cold, excessive sound, crowds); water exposure (e.g., bathing, swimming); certain foods or odors (e.g., chocolate, food dyes); missed meals; excessive or atypically strenuous exercise; illness; irregular sleep (missing a nap, delayed bedtime).</div></li><li class="half_rhythm"><div>CAPOS syndrome. Febrile illness, pregnancy.</div></li></ul><p><i>Pregnancy management:</i> Affected pregnant women should be monitored for the development of symptoms of RDP. The number of pregnant women with RDP is small, but several reports of childbirth as a trigger have been noted. Exposure to antiepileptic medication may increase the risk to the fetus of adverse outcome; that risk, however, is often less than the risk to the fetus associated with exposure to an untreated maternal seizure disorder. Discussion of the risks and benefits of using a given antiepileptic medication during pregnancy should ideally take place before conception.</p></div><div><h4 class="inline">Genetic counseling.</h4><p><i>ATP1A3</i>-related neurologic disorders are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. <i>ATP1A3</i> pathogenic variants may be inherited or occur <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>. In contrast to initial reports a <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> history is not required for a diagnosis of RDP. In AHC, pathogenic variants are more commonly <i>de novo</i> than inherited; in both RDP and CAPOS syndrome both inherited and <i>de novo</i> pathogenic variants have been observed. Each child of an individual with an <i>ATP1A3</i>-related neurologic disorder has a 50% chance of inheriting the <i>ATP1A3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Prenatal testing for pregnancies at increased risk is possible if the <i>ATP1A3</i> pathogenic variant in the family is known. The variability of presentation within a family with a known <i>ATP1A3</i> pathogenic variant further complicates <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a>. Lifelong asymptomatic individuals who harbor a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>ATP1A3</i> pathogenic variant have been reported in families with RDP.</p></div></div><div id="rapid-odp.GeneReview_Scope"><h2 id="_rapid-odp_GeneReview_Scope_"><i>GeneReview</i> Scope</h2><div id="rapid-odp.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1115/table/rapid-odp.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rapid-odp.Tc_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_rapid-odp.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ATP1A3</i>-Related Neurologic Disorders: Included Phenotypes&#x000a0;<sup>1</sup></th></tr></thead><tbody><tr><td headers="hd_h_rapid-odp.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Rapid-onset dystonia-parkinsonism (RDP)</div></li><li class="half_rhythm"><div>Alternating hemiplegia of childhood (AHC)</div></li><li class="half_rhythm"><div>Cerebellar ataxia, areflexia, <i>pes cavus</i>, optic atrophy, and sensorineural hearing loss (CAPOS) syndrome</div></li></ul>
</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">For synonyms and outdated names see <a href="#rapid-odp.Nomenclature">Nomenclature</a>.</p></div></dd><dt>1. </dt><dd><div id="rapid-odp.TF.c.1"><p class="no_margin">For other genetic causes of these phenotypes see <a href="#rapid-odp.Differential_Diagnosis">Differential Diagnosis</a>.</p></div></dd></dl></div></div></div></div><div id="rapid-odp.Diagnosis"><h2 id="_rapid-odp_Diagnosis_">Diagnosis</h2><p><i>ATP1A3</i>-related neurologic disorders represent a clinical continuum in which at least three distinct phenotypes have been delineated: rapid-onset dystonia-parkionsonism (RDP); alternating hemiplegia of childhood (ACH); and cerebellar ataxia, areflexia, <i>pes cavus</i>, optic atrophy, and sensorineural hearing loss (CAPOS) syndrome (see <a href="#rapid-odp.Clinical_Description">Clinical Description</a>). Some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have intermediate phenotypes or only a few features that do not fit well into one of these major phenotypes. Clinical diagnostic criteria for the three major <i>ATP1A3</i>-related neurologic phenotypes have been published [<a class="bk_pop" href="#rapid-odp.REF.rosewich.2017.e139">Rosewich et al 2017</a>].</p><div id="rapid-odp.Suggestive_Findings"><h3>Suggestive Findings</h3><p><i>ATP1A3</i>-related neurologic disorders <b>should be suspected</b> in individuals with the following <a href="#rapid-odp.Clinical_Features">clinical features</a> (by age) and <a href="#rapid-odp.Neuroimaging_Findings">neuroimaging findings</a> [<a class="bk_pop" href="#rapid-odp.REF.rosewich.2017.e139">Rosewich et al 2017</a>].</p><div id="rapid-odp.Clinical_Features"><h4>Clinical Features</h4><p><b>Infancy and early childhood</b></p><ul><li class="half_rhythm"><div>Alternating hemiparesis, hemiplegia, or dystonia</div></li><li class="half_rhythm"><div>Paroxysmal episodes of monocular nystagmus with or without other motor signs or symptoms</div></li><li class="half_rhythm"><div>Paroxysmal conjugate or dysconjugate ocular movement abnormalities</div></li><li class="half_rhythm"><div>Acute flaccid quadriparesis persisting for hours to days</div></li><li class="half_rhythm"><div>Recurrent paroxysmal tonic or dystonic seizure-like episodes</div></li></ul><p><b>Child or adult</b></p><ul><li class="half_rhythm"><div>Paroxysmal onset of ataxia, which becomes fixed or remains episodic</div></li><li class="half_rhythm"><div>Paroxysmal dystonia or hemidystonia</div></li><li class="half_rhythm"><div>Acute, fluctuating motor function deficits persisting for hours to days, which may include ataxia, chorea, hemiplegia, or paresis</div></li><li class="half_rhythm"><div>Paroxysmal episodes of motor signs with EEG monitoring documenting the absence of epileptiform activity</div></li><li class="half_rhythm"><div>Episodes clinically consistent with generalized or focal epilepsy (with or without ictal EEG)</div></li></ul><p><b>Any age</b></p><ul><li class="half_rhythm"><div>Asymmetric paroxysmal onset of hemiplegia or paresis, quadriplegia or paresis, spasticity, dystonia, and dyskinesia, with or without the subsequent appearance of fixed neurologic deficits</div></li><li class="half_rhythm"><div>Rostrocaudal gradient (topographic, not temporal) of fixed or fluctuating motor involvement</div></li><li class="half_rhythm"><div>Multiple environmental triggers including physical exertion, extremes of temperature, emotional stimuli, and chemicals</div></li><li class="half_rhythm"><div>Seizure-like paroxysmal tremor affecting one or more limbs or inclusive of whole-body tremors</div></li><li class="half_rhythm"><div>Paroxysmal bulbar symptoms with or without resolution over hours to days</div></li><li class="half_rhythm"><div>Suspected epileptic event with normal EEG recording during a typical spell, especially if associated with tonic or dystonic posturing or migratory paresis</div></li></ul></div><div id="rapid-odp.Neuroimaging_Findings"><h4>Neuroimaging Findings</h4><p>Brain MRI is normal in the setting of either acute onset of new neurologic symptoms or recurrent episodes of neurologic impairment.</p><p>Note: Later in the disease course in a small number of individuals with the AHC <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>, more subtle abnormalities (including diffuse cerebral atrophy and/or <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> cerebellar atrophy, or mesial temporal sclerosis) have been described [<a class="bk_pop" href="#rapid-odp.REF.sweney.2009.e534">Sweney et al 2009</a>, <a class="bk_pop" href="#rapid-odp.REF.sasaki.2014a.153">Sasaki et al 2014a</a>].</p></div></div><div id="rapid-odp.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of an <i>ATP1A3</i>-related neurologic disorder <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with classic clinical features of RDP, AHC, or CAPOS syndrome (see <a href="#rapid-odp.Clinical_Description">Clinical Description</a>) and/or by the identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>ATP1A3</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (<a class="figpopup" href="/books/NBK1115/table/rapid-odp.T.molecular_genetic_testing_us/?report=objectonly" target="object" rid-figpopup="figrapidodpTmoleculargenetictestingus" rid-ob="figobrapidodpTmoleculargenetictestingus">Table 1</a>).</p><p>Molecular genetic testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>, or <b>comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>ATP1A3</i> is performed.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>ATP1A3</i> and other genes of interest (see <a href="#rapid-odp.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (when available) including <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> and <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> may be considered. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> or genes that results in a similar clinical presentation).</div><div class="half_rhythm">For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</div></li></ul><div id="rapid-odp.T.molecular_genetic_testing_us" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in <i>ATP1A3</i>-Related Neurologic Disorders</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1115/table/rapid-odp.T.molecular_genetic_testing_us/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rapid-odp.T.molecular_genetic_testing_us_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_rapid-odp.T.molecular_genetic_testing_us_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_rapid-odp.T.molecular_genetic_testing_us_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_rapid-odp.T.molecular_genetic_testing_us_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_rapid-odp.T.molecular_genetic_testing_us_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>ATP1A3</i></td><td headers="hd_h_rapid-odp.T.molecular_genetic_testing_us_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_rapid-odp.T.molecular_genetic_testing_us_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~80%-90%&#x000a0;<sup>4,&#x000a0;5</sup></td></tr><tr><td headers="hd_h_rapid-odp.T.molecular_genetic_testing_us_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>6</sup></td><td headers="hd_h_rapid-odp.T.molecular_genetic_testing_us_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>7</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="rapid-odp.TF.1.1"><p class="no_margin">See <a href="/books/NBK1115/#rapid-odp.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="rapid-odp.TF.1.2"><p class="no_margin">See <a href="#rapid-odp.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="rapid-odp.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="rapid-odp.TF.1.4"><p class="no_margin"><a class="bk_pop" href="#rapid-odp.REF.panagiotakaki.2015.123">Panagiotakaki et al [2015]</a>, <a class="bk_pop" href="#rapid-odp.REF.viollet.2015.e0127045">Viollet et al [2015]</a>, <a class="bk_pop" href="#rapid-odp.REF.duat_rodriguez.2017.60">Duat Rodriguez et al [2017]</a></p></div></dd><dt>5. </dt><dd><div id="rapid-odp.TF.1.5"><p class="no_margin">All reported individuals with CAPOS syndrome have the same <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="figpopup" href="/books/NBK1115/table/rapid-odp.T.atp1a3_variants_discussed_in/?report=objectonly" target="object" rid-figpopup="figrapidodpTatp1a3variantsdiscussedin" rid-ob="figobrapidodpTatp1a3variantsdiscussedin">c.2452G&#x0003e;A</a> pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant [<a class="bk_pop" href="#rapid-odp.REF.rosewich.2014c.861">Rosewich et al 2014c</a>, <a class="bk_pop" href="#rapid-odp.REF.duat_rodriguez.2017.60">Duat Rodriguez et al 2017</a>], although some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals had symptoms that also overlapped with the AHC <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p></div></dd><dt>6. </dt><dd><div id="rapid-odp.TF.1.6"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>7. </dt><dd><div id="rapid-odp.TF.1.7"><p class="no_margin">No data on <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> are available.</p></div></dd></dl></div></div></div></div></div><div id="rapid-odp.Clinical_Characteristics"><h2 id="_rapid-odp_Clinical_Characteristics_">Clinical Characteristics</h2><div id="rapid-odp.Clinical_Description"><h3>Clinical Description</h3><p><i>ATP1A3</i>-related neurologic disorders represent a clinical continuum in which three main phenotypes have been described: rapid-onset dystonia-parkinsonism (RDP), alternating hemiplegia of childhood (AHC), and cerebellar ataxia, areflexia, <i>pes cavus</i>, optic atrophy, and sensorineural hearing loss (CAPOS). Individuals with intermediate phenotypes or with only a few features have also been described (see <a href="#rapid-odp.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>).</p><div id="rapid-odp.RapidOnset_DystoniaParkinsonis"><h4>Rapid-Onset Dystonia-Parkinsonism (RDP)</h4><p>Clinical diagnostic criteria for RDP include the following [<a class="bk_pop" href="#rapid-odp.REF.rosewich.2017.e139">Rosewich et al 2017</a>]:</p><ul><li class="half_rhythm"><div>Abrupt onset of dystonia with or without features of parkinsonism over a few minutes to 30 days</div></li><li class="half_rhythm"><div>A clear rostrocaudal gradient of involvement (face &#x0003e; arm &#x0003e; leg)</div></li><li class="half_rhythm"><div>Prominent bulbar findings</div><div>Note: Absence of prominent bulbar findings does not preclude the diagnosis.</div></li><li class="half_rhythm"><div>Absent or minimal response to an adequate trial of L-dopa therapy [<a class="bk_pop" href="#rapid-odp.REF.termsarasab.2015.336">Termsarasab et al 2015</a>]</div></li><li class="half_rhythm"><div>Family history consistent with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> inheritance</div><div>Note: Absence of a family history of RDP does not preclude the diagnosis.</div></li></ul><p>Additional features may include the following:</p><ul><li class="half_rhythm"><div>Appearance of symptoms after triggering events such as running, childbirth, emotional stress, or alcoholic binges</div></li><li class="half_rhythm"><div>Stability of the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> with little improvement after its initial appearance</div></li><li class="half_rhythm"><div>Low concentration of dopamine metabolites in cerebrospinal fluid in some (not all) <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals</div></li><li class="half_rhythm"><div>Absence of other parkinsonian features including pill-rolling tremor and diurnal fluctuation; minimal or no response to standard medications for parkinsonism</div></li></ul><p>The study of the clinical manifestations of RDP has focused primarily on dystonia/parkinsonism [<a class="bk_pop" href="#rapid-odp.REF.anselm.2009.400">Anselm et al 2009</a>, <a class="bk_pop" href="#rapid-odp.REF.blancoarias.2009.2370">Blanco-Arias et al 2009</a>, <a class="bk_pop" href="#rapid-odp.REF.svetel.2010.472">Svetel et al 2010</a>, <a class="bk_pop" href="#rapid-odp.REF.tarsy.2010.2213">Tarsy et al 2010</a>]. Age at onset is extremely variable, typically ranging from four to 55 years, although onset at age nine months and after age 60 years has been reported.</p><p><b>Motor findings.</b> The clinical stages of RDP may include mild antecedent dystonic symptoms, primary onset, and occasional second episodes of worsening.</p><ul><li class="half_rhythm"><div><b>Antecedent symptoms</b> have included nonspecific symptoms of dystonia, usually in the hands and arms. Some individuals reported mild limb cramping, most often involving the hands, prior to development of typical RDP following a physiologic stressor. While minimal or no tremor is typically present at onset, one individual initially had one year of parkinsonism, not dystonia, followed by abrupt onset of oromandibular dystonia with dysarthria. At least two <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals had fluctuating symptoms before the deficit became permanent; this has also been described in infants with an RDP-like presentation.</div></li><li class="half_rhythm"><div><b>Primary onset</b> is usually paroxysmal or abrupt over hours to several weeks. In all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals in two large US families, progression stopped at or before one month after onset. Many reported specific triggers consisting of either physical or psychological stress. Alcohol was a trigger in many but not all. The bulbar and arm symptoms rarely improve after the primary onset, although four individuals reported mild improvement in leg symptoms.</div></li><li class="half_rhythm"><div><b>Occasional second episodes of worsening</b> have been reported in a few individuals who experienced episodes of abrupt worsening of symptoms one to nine years after the initial onset. Because only a few <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have been reexamined over an extended time, documentation of second events is incomplete. The second events resemble the primary onset, with worsening of bulbar, arm, and leg symptoms over a similar time course. Except for these second events, little change is reported over many years in those affected individuals for whom such information is available, although the number of known affected individuals is small and lack of progression of symptoms requires further longitudinal study.</div></li></ul><p><b>Non-motor features</b> include mood disorders, substance abuse, and psychosis (see also <a href="#rapid-odp.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>). Although anxiety is also prevalent among persons with RDP, rates of anxiety did not significantly differ from family-matched controls without RDP [<a class="bk_pop" href="#rapid-odp.REF.brashear.2012b.1065">Brashear et al 2012b</a>]. Cognitive impairment including difficulty with memory and learning, psychomotor speed, attention, and executive functioning has also been reported [<a class="bk_pop" href="#rapid-odp.REF.cook.2014.344">Cook et al 2014</a>]. Seizures have been reported in children and adults [<a class="bk_pop" href="#rapid-odp.REF.brashear.2007.828">Brashear et al 2007</a>, <a class="bk_pop" href="#rapid-odp.REF.brashear.2012b.1065">Brashear et al 2012b</a>], often after the appearance of motor symptoms.</p></div><div id="rapid-odp.Alternating_Hemiplegia_of_Chil"><h4>Alternating Hemiplegia of Childhood (AHC)</h4><p>AHC is a complex neurodevelopmental syndrome that most frequently manifests in infancy or early childhood with paroxysmal neurologic symptoms that can last for minutes to hours to even days and sometimes weeks, with remission of symptoms only during sleep and the immediate period post awakening.</p><p>Clinical diagnostic criteria for AHC include some constellation of the following (see Note) [<a class="bk_pop" href="#rapid-odp.REF.rosewich.2017.e139">Rosewich et al 2017</a>]:</p><ul><li class="half_rhythm"><div>Onset of symptoms before age 18 months</div></li><li class="half_rhythm"><div>Paroxysmal disturbances including tonic or dystonic spells (either unilaterally of one or more limbs or generalized), oculomotor abnormalities (monocular or binocular nystagmus, intermittent eso- or exotropia, skew deviation, ocular bobbing, ocular flutter), and autonomic phenomena (unilateral or bilateral pupillary dilatation, flushing, pallor affecting one limb or hemibody) during hemiplegic episodes or in isolation</div></li><li class="half_rhythm"><div>Repeated attacks of hemiplegia involving either side of the body and alternating in laterality</div></li><li class="half_rhythm"><div>Episodes of quadriparesis or hemi-/quadriplegia as a separate attack or as generalization of a hemiplegic episode</div></li><li class="half_rhythm"><div>Immediate disappearance of symptoms upon sleeping (symptoms may later resume after waking)</div></li><li class="half_rhythm"><div>Evidence of developmental delay (speech and language delay, cognitive deficits) and neurologic abnormalities including choreoathetosis, dystonia, and/or ataxia</div></li></ul><p>Note: Diagnostic criteria assume that (1) initial diagnostic workup has not shown evidence of an alternative etiology (e.g., treatable metabolic disorder); (2) brain MRI is normal or with nonspecific features not identifying an alternative pathophysiology (e.g., vascular disease such as moya-moya); and (3) EEG during prolonged episodes of hemiplegia or dystonia does not provide an alternative explanation for episodes.</p><p>While neonates and young infants often present with seizure-like episodes, eye movement abnormalities, and autonomic manifestations, they can also present with episodes of flaccid quadriparesis. Paroxysmal episodic neurologic dysfunction is the predominant feature early in the disease course. As <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children age, interictal persistent neurologic dysfunction (including oculomotor apraxia, ataxia, dystonia, parkinsonism, and cognitive and behavioral dysfunction) increases.</p><p>More than 50% of children with AHC manifest clinical seizure activity by early childhood. Status epilepticus and status dystonicus can be life-threatening complications in some. For reviews, see <a class="bk_pop" href="#rapid-odp.REF.sweney.2009.e534">Sweney et al [2009]</a>, <a class="bk_pop" href="#rapid-odp.REF.panagiotakaki.2010.3598">Panagiotakaki et al [2010]</a>, <a class="bk_pop" href="#rapid-odp.REF.kansagra.2013.821">Kansagra et al [2013]</a>, <a class="bk_pop" href="#rapid-odp.REF.sasaki.2014b.482">Sasaki et al [2014b]</a>, <a class="bk_pop" href="#rapid-odp.REF.heinzen.2014.503">Heinzen et al [2014]</a>, and <a class="bk_pop" href="#rapid-odp.REF.rosewich.2017.e139">Rosewich et al [2017]</a>.</p><p>Additional paroxysmal neurologic symptoms include the following:</p><ul><li class="half_rhythm"><div>More complex dyskinesias</div></li><li class="half_rhythm"><div>Headache</div></li><li class="half_rhythm"><div>Epilepsy (focal, partial, or generalized tonic-clonic)</div></li><li class="half_rhythm"><div>Status epilepticus or status dystonicus</div></li></ul><p>Persistent, interictal neurologic symptoms that become increasingly evident with age include the following:</p><ul><li class="half_rhythm"><div>Ataxia</div></li><li class="half_rhythm"><div>Oculomotor apraxia</div></li><li class="half_rhythm"><div>Strabismus</div></li><li class="half_rhythm"><div>Hypotonia or rigidity</div></li><li class="half_rhythm"><div>Choreoathetosis</div></li><li class="half_rhythm"><div>Impaired articulation or bulbar function</div></li><li class="half_rhythm"><div>Generalized or focal dystonia</div></li><li class="half_rhythm"><div>Areflexia or hyperreflexia</div></li></ul><p>Non-motor interictal neurologic symptoms include the following:</p><ul><li class="half_rhythm"><div>Behavioral outbursts, impulsivity</div></li><li class="half_rhythm"><div>Aggression</div></li><li class="half_rhythm"><div>Mood disorders</div></li></ul><p>Other associated features in some individuals with AHC include the following:</p><ul><li class="half_rhythm"><div>Tremor</div></li><li class="half_rhythm"><div>Recurrent apnea</div></li><li class="half_rhythm"><div>Respiratory distress</div></li><li class="half_rhythm"><div>Oxygen desaturation during episodes of neurologic dysfunction</div></li><li class="half_rhythm"><div>Consistent facial features [<a class="bk_pop" href="#rapid-odp.REF.gurrieri.2016.2698">Gurrieri et al 2016</a>], including a high forehead, thin eyebrows, hypotonic appearance to the face, an exaggerated Cupid's bow of the upper lip, an everted vermillion of the lower lip, and downturned corners of the mouth</div></li><li class="half_rhythm"><div>Cardiac conduction abnormalities (T wave abnormalities and intraventricular conduction delay) with increased risk for potential fatal arrhythmia and acquired cardiomyopathy [<a class="bk_pop" href="#rapid-odp.REF.jaffer.2015.2859">Jaffer et al 2015</a>, <a class="bk_pop" href="#rapid-odp.REF.rosewich.2017.e139">Rosewich et al 2017</a>]</div></li></ul></div><div id="rapid-odp.CAPOS_Syndrome"><h4>CAPOS Syndrome</h4><p>CAPOS syndrome presents in infancy or childhood with cerebellar ataxia after a fever and eventually a characteristic set of symptoms including the following [<a class="bk_pop" href="#rapid-odp.REF.rosewich.2017.e139">Rosewich et al 2017</a>]:</p><ul><li class="half_rhythm"><div>Cerebellar ataxia</div></li><li class="half_rhythm"><div>Areflexia</div></li><li class="half_rhythm"><div><i>Pes cavus</i> (not present in all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals)</div></li><li class="half_rhythm"><div>Progressive optic atrophy</div></li><li class="half_rhythm"><div>Progressive sensorineural hearing loss</div></li></ul><p>In addition to ataxia, symptoms during the acute febrile encephalopathy may include hypotonia, flaccidity, nystagmus, strabismus, dysarthria, anarthria, lethargy, loss of consciousness, and even coma. There is usually considerable recovery within days to weeks, but persistence of some ataxia and other symptoms is typical. Additional features seen in one or more <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals include abnormal eye movements, dysphagia, autistic traits, brief seizures during acute illness, dystonia, and cognitive dysfunction [<a class="bk_pop" href="#rapid-odp.REF.nicolaides.1996.419">Nicolaides et al 1996</a>, <a class="bk_pop" href="#rapid-odp.REF.demos.2014.15">Demos et al 2014</a>, <a class="bk_pop" href="#rapid-odp.REF.heimer.2015.1749">Heimer et al 2015</a>, <a class="bk_pop" href="#rapid-odp.REF.potic.2015.453">Potic et al 2015</a>, <a class="bk_pop" href="#rapid-odp.REF.maas.2016.71">Maas et al 2016</a>, <a class="bk_pop" href="#rapid-odp.REF.duat_rodriguez.2017.60">Duat Rodriguez et al 2017</a>].</p><p>This condition has been described in nine families and in three individuals who have an apparently <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>ATP1A3</i> [<a class="bk_pop" href="#rapid-odp.REF.demos.2014.15">Demos et al 2014</a>, <a class="bk_pop" href="#rapid-odp.REF.duat_rodriguez.2017.60">Duat Rodriguez et al 2017</a>]. Onset and progression of optic atrophy and sensorineural hearing loss are not well characterized. While the course and severity of deficits can vary considerably, there appears to be progression over time.</p></div></div><div id="rapid-odp.Pathophysiology"><h3>Pathophysiology</h3><p>Neuropathology specimens from persons with RDP show changes in neuronal pathways, suggesting involvement of cerebral and cerebellar connections necessary for motor control [<a class="bk_pop" href="#rapid-odp.REF.oblak.2014.81">Oblak et al 2014</a>].</p></div><div id="rapid-odp.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Review of published studies has shown that the same <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> may lead to different phenotypes (e.g., RDP in one family but AHC in another), suggesting that <i>ATP1A3</i>-related disorders truly represent a continuum of phenotypes [<a class="bk_pop" href="#rapid-odp.REF.de_carvalho_aguiar.2004.169">de Carvalho Aguiar et al 2004</a>, <a class="bk_pop" href="#rapid-odp.REF.zanottifregonara.2008.148">Zanotti-Fregonara et al 2008</a>, <a class="bk_pop" href="#rapid-odp.REF.heinzen.2012.1030">Heinzen et al 2012</a>, <a class="bk_pop" href="#rapid-odp.REF.roubergue.2013.1457">Roubergue et al 2013</a>, <a class="bk_pop" href="#rapid-odp.REF.boelman.2014.850">Boelman et al 2014</a>, <a class="bk_pop" href="#rapid-odp.REF.rosewich.2014b.945">Rosewich et al 2014b</a>, <a class="bk_pop" href="#rapid-odp.REF.yang.2014.e97274">Yang et al 2014</a>, <a class="bk_pop" href="#rapid-odp.REF.viollet.2015.e0127045">Viollet et al 2015</a>].</p><p><b>AHC.</b> Individuals with AHC and the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> <a class="figpopup" href="/books/NBK1115/table/rapid-odp.T.atp1a3_variants_discussed_in/?report=objectonly" target="object" rid-figpopup="figrapidodpTatp1a3variantsdiscussedin" rid-ob="figobrapidodpTatp1a3variantsdiscussedin">p.Glu815Lys</a> may have earlier onset of symptoms and greater motor and cognitive impairment, and more often experience status epilepticus and respiratory paralysis [<a class="bk_pop" href="#rapid-odp.REF.sasaki.2014b.482">Sasaki et al 2014b</a>, <a class="bk_pop" href="#rapid-odp.REF.yang.2014.e97274">Yang et al 2014</a>, <a class="bk_pop" href="#rapid-odp.REF.panagiotakaki.2015.123">Panagiotakaki et al 2015</a>, <a class="bk_pop" href="#rapid-odp.REF.viollet.2015.e0127045">Viollet et al 2015</a>].</p><p><b>Intermediate and atypical phenotypes</b></p><ul><li class="half_rhythm"><div>Intermediate phenotypes, often with onset in the childhood years, have also been reported in individuals with the following pathogenic variants: <a class="figpopup" href="/books/NBK1115/table/rapid-odp.T.atp1a3_variants_discussed_in/?report=objectonly" target="object" rid-figpopup="figrapidodpTatp1a3variantsdiscussedin" rid-ob="figobrapidodpTatp1a3variantsdiscussedin">p.Gly358Asp</a>, <a class="figpopup" href="/books/NBK1115/table/rapid-odp.T.atp1a3_variants_discussed_in/?report=objectonly" target="object" rid-figpopup="figrapidodpTatp1a3variantsdiscussedin" rid-ob="figobrapidodpTatp1a3variantsdiscussedin">p.Arg756His</a>, <a class="figpopup" href="/books/NBK1115/table/rapid-odp.T.atp1a3_variants_discussed_in/?report=objectonly" target="object" rid-figpopup="figrapidodpTatp1a3variantsdiscussedin" rid-ob="figobrapidodpTatp1a3variantsdiscussedin">p.Gly867Asp</a>, <a class="figpopup" href="/books/NBK1115/table/rapid-odp.T.atp1a3_variants_discussed_in/?report=objectonly" target="object" rid-figpopup="figrapidodpTatp1a3variantsdiscussedin" rid-ob="figobrapidodpTatp1a3variantsdiscussedin">p.Asp923Asn</a>, and <a class="figpopup" href="/books/NBK1115/table/rapid-odp.T.atp1a3_variants_discussed_in/?report=objectonly" target="object" rid-figpopup="figrapidodpTatp1a3variantsdiscussedin" rid-ob="figobrapidodpTatp1a3variantsdiscussedin">p.Glu951Lys</a> [<a class="bk_pop" href="#rapid-odp.REF.anselm.2009.400">Anselm et al 2009</a>, <a class="bk_pop" href="#rapid-odp.REF.brashear.2012b.1065">Brashear et al 2012b</a>, <a class="bk_pop" href="#rapid-odp.REF.roubergue.2013.1457">Roubergue et al 2013</a>, <a class="bk_pop" href="#rapid-odp.REF.rosewich.2014a.133">Rosewich et al 2014a</a>, <a class="bk_pop" href="#rapid-odp.REF.sasaki.2014a.153">Sasaki et al 2014a</a>, <a class="bk_pop" href="#rapid-odp.REF.panagiotakaki.2015.123">Panagiotakaki et al 2015</a>, <a class="bk_pop" href="#rapid-odp.REF.pereira.2015.398">Pereira et al 2015</a>, <a class="bk_pop" href="#rapid-odp.REF.termsarasab.2015.336">Termsarasab et al 2015</a>, <a class="bk_pop" href="#rapid-odp.REF.jaffer.2017.e145">Jaffer et al 2017</a>].</div></li><li class="half_rhythm"><div>Childhood-onset schizophrenia with long-standing mild motor delays, selective mutism, and aggression was reported in a child age six years who was <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the <a class="figpopup" href="/books/NBK1115/table/rapid-odp.T.atp1a3_variants_discussed_in/?report=objectonly" target="object" rid-figpopup="figrapidodpTatp1a3variantsdiscussedin" rid-ob="figobrapidodpTatp1a3variantsdiscussedin">p.Val129Met</a> variant [<a class="bk_pop" href="#rapid-odp.REF.smedemarkmargulies.2016.a001008">Smedemark-Margulies et al 2016</a>].</div></li><li class="half_rhythm"><div>One individual with catastrophic infantile-onset epileptic encephalopathy who died at age 16 months had a novel <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="figpopup" href="/books/NBK1115/table/rapid-odp.T.atp1a3_variants_discussed_in/?report=objectonly" target="object" rid-figpopup="figrapidodpTatp1a3variantsdiscussedin" rid-ob="figobrapidodpTatp1a3variantsdiscussedin">p.Gly358Val</a> variant in <i>ATP1A3</i>. Another individual with epilepsy, episodic prolonged apnea, postnatal microcephaly, and severe developmental delays had a novel heterozygous <a class="figpopup" href="/books/NBK1115/table/rapid-odp.T.atp1a3_variants_discussed_in/?report=objectonly" target="object" rid-figpopup="figrapidodpTatp1a3variantsdiscussedin" rid-ob="figobrapidodpTatp1a3variantsdiscussedin">p.Ile363Asn</a> variant in <i>ATP1A3</i> [<a class="bk_pop" href="#rapid-odp.REF.paciorkowski.2015.422">Paciorkowski et al 2015</a>].</div></li><li class="half_rhythm"><div>Rapid-adult-onset ataxia with profound dysarthria and progressive cerebellar degeneration was reported in a single individual with a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="figpopup" href="/books/NBK1115/table/rapid-odp.T.atp1a3_variants_discussed_in/?report=objectonly" target="object" rid-figpopup="figrapidodpTatp1a3variantsdiscussedin" rid-ob="figobrapidodpTatp1a3variantsdiscussedin">p.Gly316Ser</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#rapid-odp.REF.sweadner.2016.e0151429">Sweadner at al 2016</a>].</div></li><li class="half_rhythm"><div>Approximately 12 individuals with different pathogenic variants in the amino acid residue <a class="figpopup" href="/books/NBK1115/table/rapid-odp.T.atp1a3_variants_discussed_in/?report=objectonly" target="object" rid-figpopup="figrapidodpTatp1a3variantsdiscussedin" rid-ob="figobrapidodpTatp1a3variantsdiscussedin">p.Arg756</a> [<a class="bk_pop" href="#rapid-odp.REF.yano.2017.101">Yano et al 2017</a>] have atypical features that may represent a definable <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> that is distinct from RDP, AHC, and CAPOS:</div><ul><li class="half_rhythm"><div>All <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals had an episodic course with fever-induced encephalopathy as a key defining feature. Varying associated motor deficits including hypotonia, paresis, weakness, ataxia, dystonia, and dysphagia were described.</div></li><li class="half_rhythm"><div>For those with more prominent ataxia, the name "relapsing encephalopathy with cerebellar ataxia" (designated RECA) has been proposed [<a class="bk_pop" href="#rapid-odp.REF.dard.2015.1183">Dard et al 2015</a>, <a class="bk_pop" href="#rapid-odp.REF.hully.2017.23">Hully et al 2017</a>].</div></li><li class="half_rhythm"><div>Those whose primary feature is weakness have been given the designation of FIPWE: fever-induced paroxysmal weakness and encephalopathy [<a class="bk_pop" href="#rapid-odp.REF.yano.2017.101">Yano et al 2017</a>].</div></li></ul></li></ul></div><div id="rapid-odp.Penetrance"><h3>Penetrance</h3><p><b>RDP.</b> Penetrance is incomplete. The small number of families with RDP studied to date limits the estimate of <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>; however, several members of the larger reported families have had a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>ATP1A3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> but no symptoms [<a class="bk_pop" href="#rapid-odp.REF.kramer.1999.176">Kramer et al 1999</a>, <a class="bk_pop" href="#rapid-odp.REF.de_carvalho_aguiar.2004.169">de Carvalho Aguiar et al 2004</a>, <a class="bk_pop" href="#rapid-odp.REF.brashear.2007.828">Brashear et al 2007</a>].</p><p><b>AHC.</b> Penetrance is even more uncertain, as most <i>ATP1A3</i> pathogenic variants reported to date have occurred <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>.</p><p><b>CAPOS syndrome.</b> There is no evidence of incomplete <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in the families/individuals reported to date [<a class="bk_pop" href="#rapid-odp.REF.demos.2014.15">Demos et al 2014</a>, <a class="bk_pop" href="#rapid-odp.REF.maas.2016.71">Maas et al 2016</a>, <a class="bk_pop" href="#rapid-odp.REF.duat_rodriguez.2017.60">Duat Rodriguez et al 2017</a>].</p></div><div id="rapid-odp.Nomenclature"><h3>Nomenclature</h3><p>The nomenclature of all three well-described phenotypes, based on early clinical categorization, is useful for highlighting symptoms that provide a starting point for diagnosis.</p><p><b>Rapid-onset dystonia-parkinsonism (RDP)</b> was first recognized and named by <a class="bk_pop" href="#rapid-odp.REF.dobyns.1993.2596">Dobyns et al [1993]</a> in a girl age 15 years with an abrupt onset of dystonia with severe bulbar symptoms and some signs of parkinsonism (postural instability with bradykinesia). Cerebrospinal fluid levels of dopamine metabolites were low; thus, the term "RDP" was used to describe what later came to be known as "DYT12 caused by pathogenic variants in <i>ATP1A3</i>" (DYT12 is also referred to as DYT-ATP1A3; see <a href="/books/n/gene/dystonia-ov/">Dystonia Overview</a>). Because classic signs of Parkinson disease, such as tremor, are unusual in individuals with RDP, the term "parkinsonism" in the designation "RDP" represents a subset of parkinsonian symptoms, and the disorder is classified as combined dystonia (previously called dystonia-plus) [<a class="bk_pop" href="#rapid-odp.REF.albanese.2013.863">Albanese et al 2013</a>].</p><p><b>Alternating hemiplegia of childhood (AHC)</b> was named for its most striking and diagnostic motor symptom; however, the range of manifestations show it to be a CNS disorder affecting function broadly in various brain circuits, and the disease evolves with age.</p><p><b><i>C</i>erebellar ataxia, <i>a</i>reflexia, <i>pes cavus</i>, <i>o</i>ptic atrophy, and <i>s</i>ensorineural hearing loss (CAPOS) syndrome</b> was named for a unique cluster of symptoms. It is now recognized to share characteristics with RDP and AHC; however, the fact that to date the same <i>ATP1A3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been observed in the nine unrelated families/individuals, some of whom have a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant, supports the continued use of the term.</p></div><div id="rapid-odp.Prevalence"><h3>Prevalence</h3><p><b>RDP.</b> The prevalence is not known. RDP has been described in individuals and families from the US, Europe, and Asia, and in individuals of African descent [<a class="bk_pop" href="#rapid-odp.REF.webb.1999.171">Webb et al 1999</a>, <a class="bk_pop" href="#rapid-odp.REF.de_carvalho_aguiar.2004.169">de Carvalho Aguiar et al 2004</a>, <a class="bk_pop" href="#rapid-odp.REF.brashear.2007.828">Brashear et al 2007</a>, <a class="bk_pop" href="#rapid-odp.REF.lee.2007.1808">Lee et al 2007</a>, <a class="bk_pop" href="#rapid-odp.REF.blancoarias.2009.2370">Blanco-Arias et al 2009</a>, <a class="bk_pop" href="#rapid-odp.REF.tarsy.2010.2213">Tarsy et al 2010</a>, <a class="bk_pop" href="#rapid-odp.REF.de_gusmao.2016.402">de Gusmao et al 2016</a>].</p><p><b>AHC.</b> The prevalence has been estimated at 1:1,000,000.</p><p><b>CAPOS syndrome.</b> The prevalence is not known.</p></div></div><div id="rapid-odp.Genetically_Related_Allelic_Di"><h2 id="_rapid-odp_Genetically_Related_Allelic_Di_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are currently reported to be associated with pathogenic variants in <i>ATP1A3.</i></p></div><div id="rapid-odp.Differential_Diagnosis"><h2 id="_rapid-odp_Differential_Diagnosis_">Differential Diagnosis</h2><div id="rapid-odp.RapidOnset_DystoniaParkinsonis_1"><h3>Rapid-Onset Dystonia-Parkinsonism (RDP)</h3><p>The physician needs to exclude more common and treatable forms of dystonia-parkinsonism (see <a href="/books/n/gene/dystonia-ov/">Dystonia Overview</a> and <a href="/books/n/gene/parkinson-overview/">Parkinson Disease Overview</a>). Evaluations should include brain MRI and assessment for <a href="/books/n/gene/wilson/">Wilson disease</a>. Additionally administration of L-dopa should be trialed. In RDP, the MRI is normal and the response to L-dopa is usually minimal or none, with only one reported exception [<a class="bk_pop" href="#rapid-odp.REF.termsarasab.2015.336">Termsarasab et al 2015</a>].</p><p>The differential diagnosis of RDP includes the following:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Dopa-responsive dystonia (DRD)</b> differs from RDP in the response to L-dopa, which is minimal in those with RDP [<a class="bk_pop" href="#rapid-odp.REF.bressman.2002.1780">Bressman et al 2002</a>, <a class="bk_pop" href="#rapid-odp.REF.kabakci.2005.860">Kabakci et al 2005</a>, <a class="bk_pop" href="#rapid-odp.REF.geyer.2006.780">Geyer &#x00026; Bressman 2006</a>], with only one exception [<a class="bk_pop" href="#rapid-odp.REF.termsarasab.2015.336">Termsarasab et al 2015</a>]. Furthermore, DRD typically presents in the leg and, in some reports, has been confused with cerebral palsy [<a class="bk_pop" href="#rapid-odp.REF.nygaard.1994.236">Nygaard et al 1994</a>]. "DRD" refers to the following disease entities: <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> <a href="/books/n/gene/drd/">GTPCH1-deficient DRD</a>, <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> <a href="/books/n/gene/thdrd/">TH-deficient DRD</a>, and autosomal recessive <a href="/books/n/gene/spr-def/">sepiapterin reductase-deficient DRD</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><a href="/books/n/gene/dystonia/"><b>DYT1 dystonia</b></a>, unlike RDP, has a more caudal to rostral gradient. Onset of DYT1 dystonia in older individuals is rare, whereas RDP may present abruptly after age 30 years.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Young-onset parkinsonism.</b> Individuals with young-onset parkinsonism may have limb dystonia as an early manifestation; however, unlike persons with RDP, they should have a significant and sustained response to L-dopa. Other genetic forms of Parkinson disease including <a href="/books/n/gene/pink1-pd/"><i>PINK1</i> type of young-onset Parkinson disease</a> and <a href="/books/n/gene/jpd/">parkin type of early-onset Parkinson disease</a> (both inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner) should be considered.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Possible <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> heterogeneity.</b> Although no other genes or loci are known to be associated with RDP, not all individuals with a <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> consistent with RDP have an <i>ATP1A3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; therefore, it is possible that pathogenic variants in another <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> or genes cause RDP.</div><div class="half_rhythm">A clinical diagnosis of RDP in a kindred of eight individuals who have neither a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>ATP1A3</i> nor linkage to <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 19q in the DYT12 region is apparently a phenocopy [<a class="bk_pop" href="#rapid-odp.REF.kabakci.2005.860">Kabakci et al 2005</a>]. The <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> presented at age six years with overnight onset of dysphonia, dysphagia, orofacial dystonia, and dystonia of all four limbs, findings that meet the diagnostic criteria for RDP. However, five of the eight <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals had renal disease consisting of renal hypoplasia, renal cysts, and/or end-stage renal disease, which has not been observed in individuals with RDP and <i>ATP1A3</i> pathogenic variants.</div></li></ul></div><div id="rapid-odp.Alternating_Hemiplegia_of_Chil_1"><h3>Alternating Hemiplegia of Childhood (AHC)</h3><p>Given the early onset and protean neurologic symptoms in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> infants and young children, the differential diagnosis of AHC is unavoidably broad.</p><p>It is particularly important early in the diagnostic evaluation of an individual suspected of having AHC to exclude metabolic disorders or vascular syndromes that could benefit from specific therapeutic approaches including: moya-moya disease (OMIM <a href="http://omim.org/phenotypicSeries/PS252350" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PS252350</a>); mitochondrial disorders such as pyruvate dehydrogenase deficiency (in which spells are typically accompanied by lactic acidosis; see OMIM <a href="http://omim.org/phenotypicSeries/PS312170" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PS312170</a>); and <a href="/books/n/gene/glut1/">glucose transporter type 1 deficiency syndrome</a> (Glut1-DS), which responds to a ketogenic diet.</p><p>The often prolonged episodes of hemiparesis, dystonia, or quadriplegia observed early in the course of AHC are typically not associated with epileptiform activity on EEG &#x02013; a finding that can help to distinguish AHC from infantile-onset epileptic encephalopathy syndromes (OMIM <a href="http://omim.org/phenotypicSeries/PS308350" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PS308350</a>).</p><p>The paroxysmal nature of symptoms in AHC can mimic inborn errors of neurotransmitter biosynthesis and metabolism such as aromatic L-amino acid decarboxylase deficiency (OMIM <a href="http://omim.org/entry/608643" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">608643</a>) and <a href="/books/n/gene/thdrd/">tyrosine hydroxylase deficiency</a>. Studies of CSF neurotransmitters are necessary to exclude this group of disorders, and ideally should be performed as part of the diagnostic workup early in the clinical course (and prior to <i>ATP1A3</i> <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>), since alternative treatments for these disorders (e.g., neurotransmitter precursors and pyridoxine or dopamine receptor agonist therapy) are available.</p><p>Specific disorders and alternative genetic etiologies to consider include the following:</p><ul><li class="half_rhythm"><div>Pyruvate dehydrogenase deficiency (OMIM <a href="http://omim.org/phenotypicSeries/PS312170" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PS312170</a>), <a href="/books/n/gene/melas/">MELAS</a>, and other <a href="/books/n/gene/mt-overview/">mitochondrial disorders</a></div></li><li class="half_rhythm"><div><a href="/books/n/gene/glut1/">Glut1-DS</a></div></li><li class="half_rhythm"><div>Inborn errors of neurotransmitter biosynthesis and metabolism [<a class="bk_pop" href="#rapid-odp.REF.sweney.2009.e534">Sweney et al 2009</a>], especially disorders with deficient dopamine biosynthesis including aromatic L-amino acid decarboxylase deficiency (OMIM <a href="http://omim.org/entry/608643" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">608643</a>), <a href="/books/n/gene/thdrd/">tyrosine hydroxylase deficiency</a>, dihydropteridine reductase deficiency (OMIM <a href="https://www.omim.org/entry/261630" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">261630</a>), and 6-pyruvoyl-tetrahydrobiopterin synthase deficiency (OMIM <a href="http://omim.org/entry/261640" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">261640</a>).</div></li><li class="half_rhythm"><div><i>ATP1A2</i>-related disorders. Three neurologic diseases associated with pathogenic variants in the homologous <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <i>ATP1A2</i> have some overlapping clinical manifestations: infantile seizures, <a href="/books/n/gene/fhm/">familial hemiplegic migraine</a> (FHM2), and <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> common migraine [<a class="bk_pop" href="#rapid-odp.REF.de_fusco.2003.192">De Fusco et al 2003</a>, <a class="bk_pop" href="#rapid-odp.REF.vanmolkot.2003.360">Vanmolkot et al 2003</a>, <a class="bk_pop" href="#rapid-odp.REF.bassi.2004.621">Bassi et al 2004</a>, <a class="bk_pop" href="#rapid-odp.REF.kaunisto.2004.141">Kaunisto et al 2004</a>, <a class="bk_pop" href="#rapid-odp.REF.swoboda.2004.884">Swoboda et al 2004</a>, <a class="bk_pop" href="#rapid-odp.REF.ambrosini.2005.1826">Ambrosini et al 2005</a>, <a class="bk_pop" href="#rapid-odp.REF.todt.2005.315">Todt et al 2005</a>]. Despite the related genes and manifestations of hemiplegia and seizure, <i>ATP1A2</i> is expressed mainly in astrocytes instead of neurons [<a class="bk_pop" href="#rapid-odp.REF.mcgrail.1991.381">McGrail et al 1991</a>], and the underlying pathophysiology is likely to be different from that of <i>ATP1A3</i>-related disorders [<a class="bk_pop" href="#rapid-odp.REF.swoboda.2004.884">Swoboda et al 2004</a>, <a class="bk_pop" href="#rapid-odp.REF.jen.2007.523">Jen et al 2007</a>].</div></li><li class="half_rhythm"><div><i>CACNA1A</i>-related disorders (<a href="/books/n/gene/fhm/">familial hemiplegic migraine 1</a>, <a href="/books/n/gene/ea2/">episodic ataxia 2</a>, and <a href="/books/n/gene/sca6/">spinocerebellar ataxia type 6</a>)</div></li><li class="half_rhythm"><div>SLC1A3 glutamate transporter-related disorders [<a class="bk_pop" href="#rapid-odp.REF.jen.2005.529">Jen et al 2005</a>] (episodic ataxia 6; see <a href="/books/n/gene/ataxias/">Hereditary Ataxia Overview</a>)</div></li><li class="half_rhythm"><div><i>SCN1A</i>-related disorders [<a class="bk_pop" href="#rapid-odp.REF.kim.2013.440">Kim et al 2013</a>, <a class="bk_pop" href="#rapid-odp.REF.weller.2014.1062">Weller et al 2014</a>] (<a href="/books/n/gene/gefs/"><i>SCN1A-</i>related seizure disorders</a> and <a href="/books/n/gene/fhm/">familial hemiplegic migraine 3</a>)</div></li><li class="half_rhythm"><div><i>ADCY5</i>-related disorders [<a class="bk_pop" href="#rapid-odp.REF.westenberger.2017.306">Westenberger et al 2017</a>], which include <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> dyskinesia with facial myokymia (OMIM <a href="http://omim.org/entry/606703" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">606703</a>)</div></li></ul><p><b>Locus heterogeneity</b> in AHC is strongly suggested by the identification of infants and children with a <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> meeting the classic clinical criteria for AHC but in whom no apparent <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> involving <i>ATP1A3</i> or its <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> have been identified.</p><p>In several large studies of individuals with features of AHC [<a class="bk_pop" href="#rapid-odp.REF.panagiotakaki.2015.123">Panagiotakaki et al 2015</a>, <a class="bk_pop" href="#rapid-odp.REF.viollet.2015.e0127045">Viollet et al 2015</a>], 82%-85% had pathogenic variants in <i>ATP1A3</i>, suggesting a different (unknown) genetic cause for disease in approximately 15%-20% of individuals in these cohorts.</p></div><div id="rapid-odp.CAPOS_Syndrome_1"><h3>CAPOS Syndrome</h3><p>CAPOS syndrome is unique, and each of its major symptoms has multiple etiologies as separate conditions. The combination of features, particularly sensorineural hearing loss in association with <i>pes cavus</i> deformity, elicits a rather broad differential diagnosis including mitochondrial and peroxisomal disorders.</p></div></div><div id="rapid-odp.Management"><h2 id="_rapid-odp_Management_">Management</h2><div id="rapid-odp.Evaluations_Following_Initial"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with an <i>ATP1A3</i>-related neurologic disorder, the evaluations summarized in <a class="figpopup" href="/books/NBK1115/table/rapid-odp.T.recommended_evaluations_foll/?report=objectonly" target="object" rid-figpopup="figrapidodpTrecommendedevaluationsfoll" rid-ob="figobrapidodpTrecommendedevaluationsfoll">Table 2</a> (if not performed as part of the evaluation that led to diagnosis) are recommended.</p><div id="rapid-odp.T.recommended_evaluations_foll" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Recommended Evaluations Following Initial Diagnosis of <i>ATP1A3-</i>Related Neurologic Disorders</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1115/table/rapid-odp.T.recommended_evaluations_foll/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rapid-odp.T.recommended_evaluations_foll_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_rapid-odp.T.recommended_evaluations_foll_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">System/Concern</th><th id="hd_h_rapid-odp.T.recommended_evaluations_foll_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Evaluation</th><th id="hd_h_rapid-odp.T.recommended_evaluations_foll_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comment</th></tr></thead><tbody><tr><td headers="hd_h_rapid-odp.T.recommended_evaluations_foll_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Eyes</b></td><td headers="hd_h_rapid-odp.T.recommended_evaluations_foll_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ophthalmologist consultation &#x00026; OCT for evaluation of optic atrophy</td><td headers="hd_h_rapid-odp.T.recommended_evaluations_foll_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">For individuals w/CAPOS</td></tr><tr><td headers="hd_h_rapid-odp.T.recommended_evaluations_foll_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Ears</b></td><td headers="hd_h_rapid-odp.T.recommended_evaluations_foll_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hearing specialist consultation &#x00026; audiogram to evaluate for sensorineural hearing loss</td><td headers="hd_h_rapid-odp.T.recommended_evaluations_foll_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">For individuals w/CAPOS</td></tr><tr><td headers="hd_h_rapid-odp.T.recommended_evaluations_foll_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Cardiovascular</b></td><td headers="hd_h_rapid-odp.T.recommended_evaluations_foll_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">EKG &#x00026; echocardiogram to evaluate for cardiac conduction abnormalities &#x00026; cardiomyopathy; consider referral to cardiologist</td><td headers="hd_h_rapid-odp.T.recommended_evaluations_foll_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">For individuals w/AHC</td></tr><tr><td headers="hd_h_rapid-odp.T.recommended_evaluations_foll_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Musculoskeletal</b></td><td headers="hd_h_rapid-odp.T.recommended_evaluations_foll_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Assessment for <i>pes cavus</i></td><td headers="hd_h_rapid-odp.T.recommended_evaluations_foll_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">For individuals w/CAPOS</td></tr><tr><td headers="hd_h_rapid-odp.T.recommended_evaluations_foll_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Neurologic</b></td><td headers="hd_h_rapid-odp.T.recommended_evaluations_foll_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">EEG if seizures are suspected</td><td headers="hd_h_rapid-odp.T.recommended_evaluations_foll_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">For individuals w/RDP &#x00026; AHC</td></tr><tr><td headers="hd_h_rapid-odp.T.recommended_evaluations_foll_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Sleep apnea</td><td headers="hd_h_rapid-odp.T.recommended_evaluations_foll_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Baseline polysomnogram</td></tr><tr><td headers="hd_h_rapid-odp.T.recommended_evaluations_foll_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Miscellaneous/</b><br /><b>Other</b></td><td headers="hd_h_rapid-odp.T.recommended_evaluations_foll_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neuropsychological testing to evaluate cognitive or memory problems</td><td headers="hd_h_rapid-odp.T.recommended_evaluations_foll_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">For individuals w/RDP &#x00026; AHC. Questionnaires to prompt treating clinicians to elicit history &#x00026; observations relevant to disease symptoms &#x00026; management are available; see <a href="#rapid-odp.Resources">Resources</a>.</td></tr><tr><td headers="hd_h_rapid-odp.T.recommended_evaluations_foll_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Consultation w/clinical geneticist and/or genetic counselor</td><td headers="hd_h_rapid-odp.T.recommended_evaluations_foll_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">All phenotypes</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AHC = alternating hemiplegia of childhood; CAPOS = <i>c</i>erebellar ataxia, <i>a</i>reflexia, <i>pes cavus</i>, optic atrophy, and <i>s</i>ensorineural hearing loss; OCT = optical coherence tomography; RDP = rapid-onset dystonia-parkinsonism</p></div></dd></dl></div></div></div></div><div id="rapid-odp.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><div id="rapid-odp.T.treatment_of_manifestations" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Treatment of Manifestations in Individuals with <i>ATP1A3-</i>Related Neurologic Disorders</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1115/table/rapid-odp.T.treatment_of_manifestations/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rapid-odp.T.treatment_of_manifestations_lrgtbl__"><table><thead><tr><th id="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Manifestation/Concern</th><th id="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Treatment</th><th id="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Considerations/Other</th></tr></thead><tbody><tr><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Optic atrophy</td><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Visual aids</td><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Referral to ophthalmologist</td></tr><tr><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sensorineural hearing loss</td><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Standard treatment</td><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See <a href="/books/n/gene/deafness-overview/">Hereditary Hearing Loss and Deafness Overview</a>.</td></tr><tr><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sleep apnea</td><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">CPAP or BiPAP; ENT evaluation for tonsillectomy/adenoidectomy</td><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cardiac arrhythmia and/or cardiomyopathy</td><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Standard treatment</td><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Referral to cardiologist</td></tr><tr><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Feeding difficulties or dysphagia</td><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Standard therapy; gastrostomy tube if required for severe dysphagia</td><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Individuals w/RDP</td></tr><tr><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Motor dysfunction</td><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Physical therapy and/or occupational therapy evaluation</td><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">All phenotypes</td></tr><tr><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dysarthria</td><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Speech therapy</td><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">All phenotypes</td></tr><tr><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Seizure disorder</td><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Standard treatment</td><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">All phenotypes. Seizure care plan (w/provision of rescue therapy for prolonged seizures if indicated) strongly recommended</td></tr><tr><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Acute spasms or attacks</td><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Chloral hydrate or other sleep-inducing medication (individuals w/AHC)</td><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">For either recurrent brief or more prolonged tonic or dystonic episodes associated w/alterations in consciousness; low threshold for suspicion of seizure activity</td></tr><tr><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dystonia</td><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Benzodiazepines, dopamine agonists, or levo-dopa may be helpful.</td><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">All phenotypes; may be severe</td></tr><tr><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ataxia</td><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Physical therapy</td><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">All phenotypes</td></tr><tr><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mood disorder, substance abuse, and/or psychosis</td><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Psychotherapy &#x00026; standard pharmacotherapy</td><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Individuals w/RDP</td></tr><tr><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Developmental delay</td><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Early referral for developmental support / special education, which may include physical therapy, occupational therapy, speech therapy, and/or cognitive therapy</td><td headers="hd_h_rapid-odp.T.treatment_of_manifestations_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consider referral to a neurodevelopmental specialist.</td></tr></tbody></table></div></div></div><div id="rapid-odp.Prevention_of_Primary_Manifest"><h3>Prevention of Primary Manifestations</h3><p>Note: Pallidal deep brain stimulation has not been effective [<a class="bk_pop" href="#rapid-odp.REF.deutschl_nder.2005.254">Deutschl&#x000e4;nder et al 2005</a>; <a class="bk_pop" href="#rapid-odp.REF.kamm.2008.1501">Kamm et al 2008</a>; <a class="bk_pop" href="#rapid-odp.REF.br_cke.2014.76">Br&#x000fc;cke et al 2014</a>; Brashear A, personal communication].</p></div><div id="rapid-odp.Prevention_of_Secondary_Compli"><h3>Prevention of Secondary Complications</h3><div id="rapid-odp.T.prevention_of_primary_manife" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Prevention of Primary Manifestations in Individuals with <i>ATP1A3-</i>Related Neurologic Disorders</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1115/table/rapid-odp.T.prevention_of_primary_manife/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rapid-odp.T.prevention_of_primary_manife_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_rapid-odp.T.prevention_of_primary_manife_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Manifestation/Concern</th><th id="hd_h_rapid-odp.T.prevention_of_primary_manife_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Prevention</th><th id="hd_h_rapid-odp.T.prevention_of_primary_manife_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Considerations/Other</th></tr></thead><tbody><tr><td headers="hd_h_rapid-odp.T.prevention_of_primary_manife_1_1_1_1" rowspan="5" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Spasms or attacks</td><td headers="hd_h_rapid-odp.T.prevention_of_primary_manife_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Trial of high-dose benzodiazepines (individuals w/RDP &#x00026; AHC)</td><td headers="hd_h_rapid-odp.T.prevention_of_primary_manife_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No systematic study of benzodiazepine therapy has been published.</td></tr><tr><td headers="hd_h_rapid-odp.T.prevention_of_primary_manife_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Flunarizine (individuals w/AHC)&#x000a0;<sup>1,&#x000a0;2</sup></td><td headers="hd_h_rapid-odp.T.prevention_of_primary_manife_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Abrupt withdrawal of flunarizine has been associated w/deterioration in clinical status.&#x000a0;<sup>3</sup></td></tr><tr><td headers="hd_h_rapid-odp.T.prevention_of_primary_manife_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Topiramate&#x000a0;<sup>4</sup> (individuals w/AHC)</td><td headers="hd_h_rapid-odp.T.prevention_of_primary_manife_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_rapid-odp.T.prevention_of_primary_manife_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Ketogenic diet (individuals w/AHC)</td><td headers="hd_h_rapid-odp.T.prevention_of_primary_manife_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3 individuals responded to a ketogenic diet.&#x000a0;<sup>5</sup></td></tr><tr><td headers="hd_h_rapid-odp.T.prevention_of_primary_manife_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Sleep (individuals w/AHC)</td><td headers="hd_h_rapid-odp.T.prevention_of_primary_manife_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Adult: place in a quiet, dark room.<br />Child: put down for a nap.</td></tr><tr><td headers="hd_h_rapid-odp.T.prevention_of_primary_manife_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Avoidance of triggers</td><td headers="hd_h_rapid-odp.T.prevention_of_primary_manife_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See <a href="#rapid-odp.AgentsCircumstances_to_Avoid">Agents/Circumstances to Avoid</a>.</td><td headers="hd_h_rapid-odp.T.prevention_of_primary_manife_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="rapid-odp.TF.4.1"><p class="no_margin">Flunarizine has been examined in a few small series of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals and is reported to decrease the frequency and/or severity of the episodic dystonic and/or plegic episodes [<a class="bk_pop" href="#rapid-odp.REF.silver.1993.36">Silver &#x00026; Andermann 1993</a>, <a class="bk_pop" href="#rapid-odp.REF.sasaki.2001.303">Sasaki 2001</a>, <a class="bk_pop" href="#rapid-odp.REF.pisciotta.2017.521">Pisciotta et al 2017</a>].</p></div></dd><dt>2. </dt><dd><div id="rapid-odp.TF.4.2"><p class="no_margin">Flunarizine has remained the most commonly prescribed therapy for prophylaxis of episodic neurologic dysfunction in AHC for more than two decades.</p></div></dd><dt>3. </dt><dd><div id="rapid-odp.TF.4.3"><p class="no_margin"><a class="bk_pop" href="#rapid-odp.REF.sweney.2009.e534">Sweney et al [2009]</a>, <a class="bk_pop" href="#rapid-odp.REF.sasaki.2014a.153">Sasaki et al [2014a]</a></p></div></dd><dt>4. </dt><dd><div id="rapid-odp.TF.4.4"><p class="no_margin"><a class="bk_pop" href="#rapid-odp.REF.jiang.2006.229">Jiang et al [2006]</a>, <a class="bk_pop" href="#rapid-odp.REF.chi.2012.506">Chi et al [2012]</a></p></div></dd><dt>5. </dt><dd><div id="rapid-odp.TF.4.5"><p class="no_margin"><a class="bk_pop" href="#rapid-odp.REF.ulatecampos.2014.377">Ulate-Campos et al [2014]</a>, <a class="bk_pop" href="#rapid-odp.REF.vilapueyo.2014.37">Vila-Pueyo et al [2014]</a>, <a class="bk_pop" href="#rapid-odp.REF.roubergue.2015.7">Roubergue et al [2015]</a>, <a class="bk_pop" href="#rapid-odp.REF.pisciotta.2017.521">Pisciotta et al [2017]</a></p></div></dd></dl></div></div></div><p>When dystonia is present, physical therapy to prevent contractures in the hands and feet is appropriate.</p></div><div id="rapid-odp.Surveillance"><h3>Surveillance</h3><p><b>RDP.</b> Monitor for evidence of the following:</p><ul><li class="half_rhythm"><div>Dysphagia, which (rarely) requires use of a feeding tube</div></li><li class="half_rhythm"><div>Psychiatric symptoms</div></li><li class="half_rhythm"><div>Seizures, which are reported in some individuals following acute onset of RDP</div></li></ul><p><b>AHC.</b> Monitor for evidence of seizures, which occur over time in a large proportion of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p><p><b>CAPOS syndrome.</b> Monitor for evidence of swallow dysfunction to reduce the risk of aspiration.</p></div><div id="rapid-odp.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>At-risk family members and asymptomatic individuals with an <i>ATP1A3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> are cautioned to avoid alcohol and excessive exercise.</p><p>Infections and fever are also common triggers; while practical preventive strategies are lacking, unnecessary exposure should be avoided. There is no known reason to avoid vaccinations.</p><p><b>RDP.</b> Triggers associated with the abrupt onset of RDP that should be avoided include (but are not limited to) the following:</p><ul><li class="half_rhythm"><div>Alcohol</div></li><li class="half_rhythm"><div>Fever</div></li><li class="half_rhythm"><div>Psychological stress (e.g., childbirth)</div></li><li class="half_rhythm"><div>Excessive exercise (e.g., running track)</div></li></ul><p><b>AHC.</b> Triggers associated with inducing paroxysmal episodes in AHC [<a class="bk_pop" href="#rapid-odp.REF.sweney.2009.e534">Sweney et al 2009</a>] include the following:</p><ul><li class="half_rhythm"><div>Psychological stress</div></li><li class="half_rhythm"><div>Emotional excitement</div></li><li class="half_rhythm"><div>Environmental stressors: bright light (sunlight or fluorescent lighting), excessive heat or cold, situations associated with excessive noise, crowds</div></li><li class="half_rhythm"><div>Water exposure in the form of bathing, swimming, shampooing</div></li><li class="half_rhythm"><div>Certain foods or odors: chocolate, food dyes</div></li><li class="half_rhythm"><div>Missed meals</div></li><li class="half_rhythm"><div>Excessive or atypically strenuous exercise (e.g., walking farther than usual, use of a playground swing)</div></li><li class="half_rhythm"><div>Illness</div></li><li class="half_rhythm"><div>Irregular sleep, missing a nap, delayed bedtime</div></li></ul><p><b>CAPOS syndrome.</b> Febrile illness can trigger an episode of ataxic encephalopathy and/or weakness. Pregnancy can also trigger worsening of symptoms in women with CAPOS syndrome [<a class="bk_pop" href="#rapid-odp.REF.chang.2018.235">Chang et al 2018</a>].</p></div><div id="rapid-odp.Evaluation_of_Relatives_at_Ris"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate the at-risk family members of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual in order to identify as early as possible those who should avoid triggers such as alcohol and excessive exercise (see <a href="#rapid-odp.AgentsCircumstances_to_Avoid">Agents/Circumstances to Avoid</a>).</p><p>Evaluations can include the following:</p><ul><li class="half_rhythm"><div>Molecular genetic testing if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is known</div></li><li class="half_rhythm"><div>Neurologic evaluation if the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is not known</div></li></ul><p>See <a href="#rapid-odp.Related_Genetic_Counseling_Iss">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="rapid-odp.Pregnancy_Management"><h3>Pregnancy Management</h3><p>The pregnancy of a woman should be monitored for symptoms of RDP, onset of which has followed childbirth in some (not all) women who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an <i>ATP1A3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p>In principle, abortion or cesarean section could be sufficiently stressful to trigger an episode.</p><p>In general, women with epilepsy or a seizure disorder from any cause are at greater risk for mortality during pregnancy than pregnant women without a seizure disorder; use of antiepileptic medication during pregnancy reduces this risk. However, exposure to antiepileptic medication may increase the risk for adverse fetal outcome (depending on the drug used, the dose, and the stage of pregnancy at which medication is taken). Nevertheless, the risk of an adverse outcome to the fetus from antiepileptic medication exposure is often less than that associated with exposure to an untreated maternal seizure disorder. Therefore, use of antiepileptic medication to treat a maternal seizure disorder during pregnancy is typically recommended. Discussion of the risks and benefits of using a given antiepileptic drug during pregnancy should ideally take place before conception. Transitioning to a lower-risk medication before pregnancy may be possible [<a href="https://www.ncbi.nlm.nih.gov/books/NBK1293/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Sarma et al 2016</a>].</p><p>See <a href="http://www.mothertobaby.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MotherToBaby</a> for further information on medication use during pregnancy.</p></div><div id="rapid-odp.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div><div id="rapid-odp.Other"><h3>Other</h3><p>Levodopa and dopamine agonists usually provide little benefit, but are an important part of the diagnostic evaluation.</p><p>There is no known way to prevent the abrupt onset of symptoms in RDP. During the abrupt onset, no acute treatment other than symptomatic relief of dystonia is available.</p></div></div><div id="rapid-odp.Genetic_Counseling"><h2 id="_rapid-odp_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="rapid-odp.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p><i>ATP1A3</i>-related neurologic disorders are inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="rapid-odp.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an <i>ATP1A3</i>-related neurologic disorder may have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</div><ul><li class="half_rhythm"><div>Many individuals diagnosed with a relatively less severe <i>ATP1A3</i>-related neurologic disorder (e.g., RDP or CAPOS) inherited an <i>ATP1A3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> from an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent [<a class="bk_pop" href="#rapid-odp.REF.de_carvalho_aguiar.2004.169">de Carvalho Aguiar et al 2004</a>, <a class="bk_pop" href="#rapid-odp.REF.demos.2014.15">Demos et al 2014</a>]. In some families, an affected individual may inherit an <i>ATP1A3</i> pathogenic variant from a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a>, asymptomatic parent; this is more frequently observed when the affected individual has RDP.</div></li><li class="half_rhythm"><div>Very rarely, an individual with a more severe <i>ATP1A3</i>-related neurologic disorder (e.g., AHC) inherited an <i>ATP1A3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> from an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent.</div></li></ul></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an <i>ATP1A3</i>-related neurologic disorder may have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (i.e., neither parent is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for the <i>ATP1A3</i> pathogenic variant).</div><ul><li class="half_rhythm"><div><i>De novo</i> pathogenic variants are common in RDP.</div></li><li class="half_rhythm"><div>CAPOS syndrome is known to have resulted from a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in at least three individuals [<a class="bk_pop" href="#rapid-odp.REF.demos.2014.15">Demos et al 2014</a>, <a class="bk_pop" href="#rapid-odp.REF.rosewich.2014a.133">Rosewich et al 2014a</a>, <a class="bk_pop" href="#rapid-odp.REF.maas.2016.71">Maas et al 2016</a>].</div></li><li class="half_rhythm"><div>AHC is usually the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li></ul></li><li class="half_rhythm"><div>Recommendations for the evaluation of parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (i.e., neither parent is known to be <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> with an <i>ATP1A3</i>-related neurologic disorder) include obtaining a detailed medical and family history, examination by a movement disorder specialist, and <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of both parents for the <i>ATP1A3</i> pathogenic variant identified in the proband.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, possible explanations include a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in the proband or <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent (germline mosaicism has been reported [<a class="bk_pop" href="#rapid-odp.REF.hully.2017.23">Hully et al 2017</a>]).</div></li><li class="half_rhythm"><div>Evaluation of parents may determine that one is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> but has escaped previous diagnosis because of a milder phenotypic presentation or reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> (reduced penetrance is seen in RDP but has not been reported in CAPOS syndrome; penetrance in AHC is currently unknown). Therefore, an apparently negative family history cannot be confirmed until appropriate evaluations and genetic testing have been performed.</div></li><li class="half_rhythm"><div>Note: If the parent is the individual in whom the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> first occurred, s/he may have <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> for the variant and may be mildly/minimally <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The risk to the sibs of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> depends on the genetic status of the proband's parents.</div></li><li class="half_rhythm"><div>If a parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> and/or has an <i>ATP1A3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the risk to the sibs of inheriting the pathogenic variant is 50%. Sibs who inherit the <i>ATP1A3</i> pathogenic variant typically share the same phenotypic features as the proband; however, reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> (see <a href="#rapid-odp.Penetrance">Penetrance</a>) and <a class="def" href="/books/n/gene/glossary/def-item/intrafamilial-variability/">intrafamilial variability</a> have been observed. In one family, affected individuals were described as having typical and atypical AHC (i.e., intermediate phenotypes between AHC and RDP) [<a class="bk_pop" href="#rapid-odp.REF.roubergue.2013.1457">Roubergue et al 2013</a>]. The occurrence of both mild and severe forms of <i>ATP1A3</i>-related neurologic disorders have been reported in the same family.</div></li><li class="half_rhythm"><div>If the parents have not been tested for the <i>ATP1A3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> but are clinically unaffected, sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> are still at increased risk for an <i>ATP1A3</i>-related neurologic disorder because of the possibility of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> parent (see <a href="#rapid-odp.Penetrance">Penetrance</a>) or the possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> (germline mosaicism has been reported [<a class="bk_pop" href="#rapid-odp.REF.hully.2017.23">Hully et al 2017</a>]).</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with RDP, AHC, or CAPOS syndrome has a 50% chance of inheriting the <i>ATP1A3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members.</b> The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent has the <i>ATP1A3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members may be at risk.</p></div><div id="rapid-odp.Related_Genetic_Counseling_Iss"><h3>Related Genetic Counseling Issues</h3><p><b>Predictive testing</b> for at-risk asymptomatic adult family members requires prior identification of the <i>ATP1A3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family.</p><p><b>Issues unique to RDP.</b> Because of the sudden onset of RDP, at-risk individuals may become hypervigilant about symptoms. Serious psychological issues have been observed in families [<a class="bk_pop" href="#rapid-odp.REF.brashear.2012a.1168">Brashear et al 2012a</a>].</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> condition has the pathogenic variant identified in the proband or clinical evidence of the disorder, the pathogenic variant is likely <i>de novo</i>. However, non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) and undisclosed adoption could also be explored.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="rapid-odp.Prenatal_Testing_and_Preimplan"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>ATP1A3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="rapid-odp.Resources"><h2 id="_rapid-odp_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Alternating Hemiplegia of Childhood Foundation (AHCF)</b></div><div>2000 Town Center</div><div>Suite 1900</div><div>Southfield MI 48075</div><div><b>Phone:</b> 313-663-7772</div><div><b>Fax:</b> 313-733-8987</div><div><b>Email:</b> sharon@ahckids.org</div><div><a href="http://ahckids.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ahckids.org</a></div></li><li class="half_rhythm"><div><b>Cure AHC, Inc.</b></div><div>8480 Honeycutt Road</div><div>Suite 200</div><div>Raleigh NC 27615</div><div><b>Phone:</b> 919-488-4217</div><div><a href="http://cureahc.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cureahc.org</a></div></li><li class="half_rhythm"><div><b>Dystonia Medical Research Foundation</b></div><div>One East Wacker Drive</div><div>Suite 1730</div><div>Chicago IL 60601-1905</div><div><b>Phone:</b> 800-377-3978 (toll-free); 312-755-0198</div><div><b>Fax:</b> 312-803-0138</div><div><b>Email:</b> dystonia@dystonia-foundation.org</div><div><a href="https://dystonia-foundation.org/what-is-dystonia/types-dystonia/rapid-onset/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Rapid-Onset Dystonia Parkinsonism</a></div></li><li class="half_rhythm"><div><b>American Parkinson Disease Association (APDA)</b></div><div>135 Parkinson Avenue</div><div>Staten Island NY 10305</div><div><b>Phone:</b> 800-223-2732 (toll-free); 718-981-8001</div><div><b>Fax:</b> 718-981-4399</div><div><b>Email:</b> apda@apdaparkinson.org</div><div><a href="http://www.apdaparkinson.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.apdaparkinson.org</a></div></li><li class="half_rhythm"><div><b>Parkinson's Foundation</b></div><div>200 SE 1st Street</div><div>Suite 800</div><div>Miami FL 33131</div><div><b>Phone:</b> 800-4PD-INFO (473-4636)</div><div><b>Email:</b> contact@parkinson.org</div><div><a href="http://www.parkinson.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.parkinson.org</a></div></li><li class="half_rhythm"><div><b>Global Dystonia Registry</b></div><div><a href="http://www.globaldystoniaregistry.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.globaldystoniaregistry.org</a></div></li><li class="half_rhythm"><div><b>US-International Alternating Hemiplegia of Childhood Registry</b></div><div><b>Email:</b> sharon@ahckids.org</div><div><a href="http://ahckids.org/research/databases/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">AHC Clinical Research Registry</a></div></li></ul></div><div id="rapid-odp.Molecular_Genetics"><h2 id="_rapid-odp_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="rapid-odp.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>ATP1A3-Related Neurologic Disorders: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1115/table/rapid-odp.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rapid-odp.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_rapid-odp.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_rapid-odp.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_rapid-odp.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_rapid-odp.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_rapid-odp.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_rapid-odp.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_rapid-odp.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/478" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>ATP1A3</i></a></td><td headers="hd_b_rapid-odp.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=478" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">19q13<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_rapid-odp.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P13637" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Sodium/potassium-transporting ATPase subunit alpha-3</a></td><td headers="hd_b_rapid-odp.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/ATP1A3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ATP1A3 database</a></td><td headers="hd_b_rapid-odp.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=ATP1A3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ATP1A3</a></td><td headers="hd_b_rapid-odp.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=ATP1A3[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ATP1A3</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="rapid-odp.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="rapid-odp.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for ATP1A3-Related Neurologic Disorders (<a href="/omim/128235,182350,601338,614820" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1115/table/rapid-odp.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rapid-odp.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/128235" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">128235</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DYSTONIA 12; DYT12</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/182350" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">182350</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ATPase, Na+/K+ TRANSPORTING, ALPHA-3 POLYPEPTIDE; ATP1A3</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/601338" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">601338</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CEREBELLAR ATAXIA, AREFLEXIA, PES CAVUS, OPTIC ATROPHY, AND SENSORINEURAL HEARING LOSS; CAPOS</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/614820" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">614820</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ALTERNATING HEMIPLEGIA OF CHILDHOOD 2; AHC2</td></tr></tbody></table></div></div><div id="rapid-odp.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p>Virtually all pathogenic variants that have been studied experimentally make one-residue changes to the protein and reduce activity, Na<sup>+</sup> affinity, or the stability of the protein. There is a tendency for high inhibition with stable protein to manifest as AHC, while pathogenic variants associated with RDP retain some activity or result in poor protein expression [reviewed in <a class="bk_pop" href="#rapid-odp.REF.heinzen.2014.503">Heinzen et al 2014</a>].</p><p>The Na,K-ATPases convert metabolic energy by moving Na<sup>+</sup> ions out of the cell and K<sup>+</sup> ions into the cell, restoring the ion gradients reduced by the activity of ion channels and Na<sup>+</sup>-dependent carriers. In the central nervous system (CNS), the Na,K-ATPase is harnessed for reuptake of glutamate and other transmitters, extracellular K<sup>+</sup> buffering, extrusion of Ca<sup>2+</sup> by Na<sup>+</sup>:Ca<sup>2+</sup> exchange, and the regulation of cell volume. Because it transports three Na<sup>+</sup> ions out of the cell for every two K<sup>+</sup> ions transported in, it is electrogenic and makes a small direct hyperpolarizing contribution to membrane potential.</p><p>Na,K-ATPase has three types of subunits (alpha, beta, and FXYD), and each subunit has multiple <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a>.</p><ul><li class="half_rhythm"><div>The catalytic alpha subunit has three <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> (alpha 1, 2, and 3) that are expressed in the CNS by three distinct genes [<a class="bk_pop" href="#rapid-odp.REF.moseley.2003.5317">Moseley et al 2003</a>]. Although it is found in a few peripheral cell types, the alpha 3 isoform is expressed exclusively in neurons in the CNS [<a class="bk_pop" href="#rapid-odp.REF.mcgrail.1991.381">McGrail et al 1991</a>].</div></li><li class="half_rhythm"><div>Three beta subunits required for Na,K-ATPase function are also expressed in the CNS.</div></li><li class="half_rhythm"><div>The FXYD subunit regulates and modifies the properties of the complex; at least three FXYD subunits are expressed in the CNS.</div></li></ul><p>A review [<a class="bk_pop" href="#rapid-odp.REF.heinzen.2014.503">Heinzen et al 2014</a>] includes information on animal models of rapid-onset dystonia-parkinsonism.</p><p><b>Gene structure.</b>
<i>ATP1A3</i> comprises 23 exons; <a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_152296.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_152296.4</a> is the predominant transcript. Additional transcripts have been described; for a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1115/#rapid-odp.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Benign variants.</b> Several common coding SNPs are reported in <a href="/SNP" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">dbSNP</a>.</p><p><b>Pathogenic variants</b></p><ul><li class="half_rhythm"><div class="half_rhythm"><b>RDP.</b> To date, at least 20 <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> or small <a class="def" href="/books/n/gene/glossary/def-item/indel/">indel</a> variants have been described as causative of RDP in both <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> cases and <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (resulting from a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>) [<a class="bk_pop" href="#rapid-odp.REF.heinzen.2014.503">Heinzen et al 2014</a>, <a class="bk_pop" href="#rapid-odp.REF.rosewich.2014b.945">Rosewich et al 2014b</a>]. The variant most frequently reported in RDP is <a class="figpopup" href="/books/NBK1115/table/rapid-odp.T.atp1a3_variants_discussed_in/?report=objectonly" target="object" rid-figpopup="figrapidodpTatp1a3variantsdiscussedin" rid-ob="figobrapidodpTatp1a3variantsdiscussedin">p.Thr613Met</a> (~26% both <i>de novo</i> and familial occurrence) [<a class="bk_pop" href="#rapid-odp.REF.de_carvalho_aguiar.2004.169">de Carvalho Aguiar et al 2004</a>, <a class="bk_pop" href="#rapid-odp.REF.brashear.2007.828">Brashear et al 2007</a>, <a class="bk_pop" href="#rapid-odp.REF.lee.2007.1808">Lee et al 2007</a>, <a class="bk_pop" href="#rapid-odp.REF.mckeon.2007.1325">McKeon et al 2007</a>, <a class="bk_pop" href="#rapid-odp.REF.barbano.2012.737">Barbano et al 2012</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>AHC.</b> To date, pathogenic variants reported in individuals with the classic AHC <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> are largely different from those reported with RDP; however, some overlap exists.</div><div class="half_rhythm">More than 85 pathogenic variants have been reported to result in an AHC <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals have a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; however, at least two <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> cases with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> inheritance have been reported as well as affected identical twins. Three pathogenic variants &#x02013; p.Asp801Asn (~40%), p.Glu815Lys (~20%), and p.Gly947Arg (~10%) &#x02013; account for more than two thirds of the <i>de novo</i> pathogenic variants observed to date [<a class="bk_pop" href="#rapid-odp.REF.panagiotakaki.2015.123">Panagiotakaki et al 2015</a>, <a class="bk_pop" href="#rapid-odp.REF.viollet.2015.e0127045">Viollet et al 2015</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><b>CAPOS syndrome.</b> All reported families and individuals with CAPOS syndrome have the same unique <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant, p.Glu818Lys [<a class="bk_pop" href="#rapid-odp.REF.duat_rodriguez.2017.60">Duat Rodriguez et al 2017</a>].</div></li></ul><div id="rapid-odp.T.atp1a3_variants_discussed_in" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p><i>ATP1A3</i> Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1115/table/rapid-odp.T.atp1a3_variants_discussed_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rapid-odp.T.atp1a3_variants_discussed_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">c.385G&#x0003e;A</td><td headers="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">p.Val129Met</td><td headers="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_3" rowspan="16" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_152296.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_152296<wbr style="display:inline-block"></wbr>​.4</a><br /><a href="https://www.ncbi.nlm.nih.gov/protein/NP_689509.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_689509<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">c.946G&#x0003e;A</td><td headers="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">p.Gly316Ser</td></tr><tr><td headers="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">c.1073G&#x0003e;T</td><td headers="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">p.Gly358Val</td></tr><tr><td headers="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">c.1073G&#x0003e;A</td><td headers="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">p.Gly358Asp</td></tr><tr><td headers="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">c.1088T&#x0003e;A</td><td headers="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">p.Ile363Asn</td></tr><tr><td headers="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">c.1838C&#x0003e;T</td><td headers="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">p.Thr613Met</td></tr><tr><td headers="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">c.2266C&#x0003e;T</td><td headers="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">p.Arg756Cys</td></tr><tr><td headers="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">c.2267G&#x0003e;A</td><td headers="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">p.Arg756His</td></tr><tr><td headers="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">c.2267G&#x0003e;T</td><td headers="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">p.Arg756Leu</td></tr><tr><td headers="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">c.2401G&#x0003e;A</td><td headers="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">p.Asp801Asn</td></tr><tr><td headers="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">c.2443G&#x0003e;A</td><td headers="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">p.Glu815Lys</td></tr><tr><td headers="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">c.2452G&#x0003e;A</td><td headers="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">p.Glu818Lys</td></tr><tr><td headers="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">c.2600G&#x0003e;A</td><td headers="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">p.Gly867Asp</td></tr><tr><td headers="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">c.2767G&#x0003e;A</td><td headers="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">p.Asp923Asn</td></tr><tr><td headers="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">c.2839G&#x0003e;A or C</td><td headers="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">p.Gly947Arg</td></tr><tr><td headers="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">c.2851G&#x0003e;A</td><td headers="hd_h_rapid-odp.T.atp1a3_variants_discussed_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">p.Glu951Lys</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>ATP1A3</i> encodes the alpha 3 subunit of the sodium/potassium-transporting ATPase (Na,K-ATPase), which comprises 1,013 amino acid residues.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Both functional studies and structural analysis of the alpha 3 subunit of the Na,K-ATPase suggest that <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants impair enzyme activity or stability [<a class="bk_pop" href="#rapid-odp.REF.de_carvalho_aguiar.2004.169">de Carvalho Aguiar et al 2004</a>, <a class="bk_pop" href="#rapid-odp.REF.heinzen.2012.1030">Heinzen et al 2012</a>]; however, it is not known whether this loss of function occurs by <a class="def" href="/books/n/gene/glossary/def-item/haploinsufficiency/">haploinsufficiency</a> or <a class="def" href="/books/n/gene/glossary/def-item/dominant-negative/">dominant-negative</a> effects.</p><p>Functional biochemical studies with several pathogenic variants associated with the RDP <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> all show reduced Na<sup>+</sup> affinity suggesting that defects in the handling of Na<sup>+</sup> may be a major factor in the development and pathology of RDP [<a class="bk_pop" href="#rapid-odp.REF.rodacker.2006.18539">Rodacker et al 2006</a>, <a class="bk_pop" href="#rapid-odp.REF.blancoarias.2009.2370">Blanco-Arias et al 2009</a>, <a class="bk_pop" href="#rapid-odp.REF.einholm.2010.26245">Einholm et al 2010</a>].</p></div></div><div id="rapid-odp.References"><h2 id="_rapid-odp_References_">References</h2><div id="rapid-odp.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.albanese.2013.863">Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, Hallett M, Jankovic J, Jinnah HA, Klein C, Lang AE, Mink JW, Teller JK. Phenomenology and classification of dystonia: a consensus update. <span><span class="ref-journal">Mov Disord. </span>2013;<span class="ref-vol">28</span>:863–73.</span> [<a href="/pmc/articles/PMC3729880/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3729880</span></a>] [<a href="/pubmed/23649720" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23649720</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.ambrosini.2005.1826">Ambrosini A, D'Onofrio M, Grieco GS, Di Mambro A, Montagna G, Fortini D, Nicoletti F, Nappi G, Sances G, Schoenen J, Buzzi MG, Santorelli FM, Pierelli F. Familial basilar migraine associated with a new mutation in the ATP1A2 gene. <span><span class="ref-journal">Neurology. </span>2005;<span class="ref-vol">65</span>:1826–8.</span> [<a href="/pubmed/16344534" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16344534</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.anselm.2009.400">Anselm IA, Sweadner KJ, Gollamudi S, Ozelius LJ, Darras BT. Rapid-onset dystonia-parkinsonism in a child with a novel atp1a3 gene mutation. <span><span class="ref-journal">Neurology. </span>2009;<span class="ref-vol">73</span>:400–1.</span> [<a href="/pmc/articles/PMC2833268/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2833268</span></a>] [<a href="/pubmed/19652145" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19652145</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.barbano.2012.737">Barbano RL, Hill DF, Snively BM, Light LS, Boggs N, McCall WV, Stacy M, Ozelius L, Sweadner KJ, Brashear A. New triggers and non-motor findings in a family with rapid-onset dystonia-parkinsonism. <span><span class="ref-journal">Parkinsonism Relat Disord. </span>2012;<span class="ref-vol">18</span>:737–41.</span> [<a href="/pmc/articles/PMC3753404/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3753404</span></a>] [<a href="/pubmed/22534615" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22534615</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.bassi.2004.621">Bassi MT, Bresolin N, Tonelli A, Nazos K, Crippa F, Baschirotto C, Zucca C, Bersano A, Dolcetta D, Boneschi FM, Barone V, Casari G. A novel mutation in the ATP1A2 gene causes alternating hemiplegia of childhood. <span><span class="ref-journal">J Med Genet. </span>2004;<span class="ref-vol">41</span>:621–8.</span> [<a href="/pmc/articles/PMC1735877/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735877</span></a>] [<a href="/pubmed/15286158" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15286158</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.blancoarias.2009.2370">Blanco-Arias P, Einholm AP, Mamsa H, Concheiro C, Guti&#x000e9;rrez-de-Ter&#x000e1;n H, Romero J, Toustrup-Jensen MS, Carracedo A, Jen JC, Vilsen B, Sobrido MJ. A C-terminal mutation of ATP1A3 underscores the crucial role of sodium affinity in the pathophysiology of rapid-onset dystonia-parkinsonism. <span><span class="ref-journal">Hum Mol Genet. </span>2009;<span class="ref-vol">18</span>:2370–7.</span> [<a href="/pubmed/19351654" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19351654</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.boelman.2014.850">Boelman C, Lagman-Bartolome AM, MacGregor DL, McCabe J, Logan WJ, Minassian BA. Identical ATP1A3 mutation causes alternating hemiplegia of childhood and rapid-onset dystonia parkinsonism phenotypes. <span><span class="ref-journal">Pediatr Neurol. </span>2014;<span class="ref-vol">51</span>:850–3.</span> [<a href="/pubmed/25439493" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25439493</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.brashear.2012a.1168">Brashear A, Cook JF, Hill DF, Amponsah A, Snively BM, Light L, Boggs N, Suerken CK, Stacy M, Ozelius L, Sweadner KJ, McCall WV. Psychiatric disorders in rapid-onset dystonia-parkinsonism. <span><span class="ref-journal">Neurology. </span>2012a;<span class="ref-vol">79</span>:1168–73.</span> [<a href="/pmc/articles/PMC3525305/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3525305</span></a>] [<a href="/pubmed/22933743" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22933743</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.brashear.2007.828">Brashear A, Dobyns WB, de Carvalho Aguiar P, Borg M, Frijns CJ, Gollamudi S, Green A, Guimaraes J, Haake BC, Klein C, Linazasoro G, Munchau A, Raymond D, Riley D, Saunders-Pullman R, Tijssen MA, Webb D, Zaremba J, Bressman SB, Ozelius LJ. The phenotypic spectrum of rapid-onset dystonia-parkinsonism (RDP) and mutations in the ATP1A3 gene. <span><span class="ref-journal">Brain. </span>2007;<span class="ref-vol">130</span>:828–35.</span> [<a href="/pubmed/17282997" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17282997</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.brashear.2012b.1065">Brashear A, Mink JW, Hill DF, Boggs N, McCall WV, Stacy MA, Snively B, Light LS, Sweadner KJ, Ozelius LJ, Morrison L. ATP1A3 mutations in infants: a new rapid-onset dystonia-parkinsonism phenotype characterized by motor delay and ataxia. <span><span class="ref-journal">Dev Med Child Neurol. </span>2012b;<span class="ref-vol">54</span>:1065–7.</span> [<a href="/pmc/articles/PMC3465467/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3465467</span></a>] [<a href="/pubmed/22924536" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22924536</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.bressman.2002.1780">Bressman SB, Raymond D, Wendt K, Saunders-Pullman R, De Leon D, Fahn S, Ozelius L, Risch N. Diagnostic criteria for dystonia in DYT1 families. <span><span class="ref-journal">Neurology. </span>2002;<span class="ref-vol">59</span>:1780–2.</span> [<a href="/pubmed/12473770" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12473770</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.br_cke.2014.76">Br&#x000fc;cke C, Horn A, Huppke P, Kupsch A, Schneider G, Kuhn AA. Failure of pallidal deep brain stimulation in a case of rapid-onset dystonia-parkinsonism (DYT12). <span><span class="ref-journal">Mov Disord Clin Pract. </span>2014;<span class="ref-vol">2</span>:76–8.</span> [<a href="/pmc/articles/PMC6353499/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6353499</span></a>] [<a href="/pubmed/30713884" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30713884</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.chang.2018.235">Chang IJ, Adam MP, Jayadev S, Bird TD, Natarajan N, Glass IA. Novel pregnancy-triggered episodes of CAPOS syndrome. <span><span class="ref-journal">Am J Med Genet A. </span>2018;<span class="ref-vol">176</span>:235–40.</span> [<a href="/pmc/articles/PMC5726903/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5726903</span></a>] [<a href="/pubmed/29090527" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29090527</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.chi.2012.506">Chi LY, Zhao XH, Liu XW, Jiang WJ, Chi ZF, Wang SJ. Alternating hemiplegia of childhood in Chinese following long-term treatment with flunarizine or topiramate. <span><span class="ref-journal">Int J Neurosci. </span>2012;<span class="ref-vol">122</span>:506–10.</span> [<a href="/pubmed/22494152" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22494152</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.cook.2014.344">Cook JF, Hill DF, Snively BM, Suerken CK, Haq I, Stacy M, McCall WV, Ozelius LJ, Sweadner KJ, Brashear A. Cognitive impairment in rapid-onset dystonia-parkinsonism. <span><span class="ref-journal">Mov Disord. </span>2014;<span class="ref-vol">29</span>:344–50.</span> [<a href="/pmc/articles/PMC3960305/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3960305</span></a>] [<a href="/pubmed/24436111" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24436111</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.dard.2015.1183">Dard R, Mignot C, Durr A, Lesca G, Sanlaville D, Roze E, Mochel F. Relapsing encephalopathy with cerebellar ataxia related to an ATP1A3 mutation. <span><span class="ref-journal">Dev Med Child Neurol. </span>2015;<span class="ref-vol">57</span>:1183–6.</span> [<a href="/pubmed/26400718" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26400718</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.de_carvalho_aguiar.2004.169">de Carvalho Aguiar P, Sweadner KJ, Penniston JT, Zaremba J, Liu L, Caton M, Linazasoro G, Borg M, Tijssen MA, Bressman SB, Dobyns WB, Brashear A, Ozelius LJ. Mutations in the Na+/K+ -ATPase alpha3 gene ATP1A3 are associated with rapid-onset dystonia parkinsonism. <span><span class="ref-journal">Neuron. </span>2004;<span class="ref-vol">43</span>:169–75.</span> [<a href="/pubmed/15260953" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15260953</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.de_fusco.2003.192">De Fusco M, Marconi R, Silvestri L, Atorino L, Rampoldi L, Morgante L, Ballabio A, Aridon P, Casari G. Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump alpha2 subunit associated with familial hemiplegic migraine type 2. <span><span class="ref-journal">Nat Genet. </span>2003;<span class="ref-vol">33</span>:192–6.</span> [<a href="/pubmed/12539047" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12539047</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.de_gusmao.2016.402">de Gusmao CM, Dy M, Sharma N. Beyond dystonia-parkinsonism: chorea and ataxia with ATP1A3 mutations. <span><span class="ref-journal">Mov Disord Clin Pract. </span>2016;<span class="ref-vol">3</span>:402–4.</span> [<a href="/pmc/articles/PMC6178757/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6178757</span></a>] [<a href="/pubmed/30363590" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30363590</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.demos.2014.15">Demos MK, van Karnebeek CD, Ross CJ, Adam S, Shen Y, Zhan SH, Shyr C, Horvath G, Suri M, Fryer A, Jones SJ, Friedman JM, et al.  A novel recurrent mutation in ATP1A3 causes CAPOS syndrome. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2014;<span class="ref-vol">9</span>:15.</span> [<a href="/pmc/articles/PMC3937150/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3937150</span></a>] [<a href="/pubmed/24468074" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24468074</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.deutschl_nder.2005.254">Deutschl&#x000e4;nder A, Asmus F, Gasser T, Steude U, Botzel K. Sporadic rapid-onset dystonia-parkinsonism syndrome: failure of bilateral pallidal stimulation. <span><span class="ref-journal">Mov Disord. </span>2005;<span class="ref-vol">20</span>:254–7.</span> [<a href="/pubmed/15455448" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15455448</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.dobyns.1993.2596">Dobyns WB, Ozelius LJ, Kramer PL, Brashear A, Farlow MR, Perry TR, Walsh LE, Kasarskis EJ, Butler IJ, Breakefield XO. Rapid-onset dystonia-parkinsonism. <span><span class="ref-journal">Neurology. </span>1993;<span class="ref-vol">43</span>:2596–602.</span> [<a href="/pubmed/8255463" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8255463</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.duat_rodriguez.2017.60">Duat Rodriguez A, Prochazkova M, Santos Santos S, Rubio Cabezas O, Cantarin Extremera V, Gonzalez-Gutierrez-Solana L. Early diagnosis of CAPOS syndrome before acute-onset ataxia-review of the literature and a new family. <span><span class="ref-journal">Pediatr Neurol. </span>2017;<span class="ref-vol">71</span>:60–4.</span> [<a href="/pubmed/28483396" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28483396</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.einholm.2010.26245">Einholm AP, Toustrup-Jensen MS, Holm R, Andersen JP, Vilsen B. The rapid-onset dystonia parkinsonism mutation D923N of the Na+, K+-ATPase alpha3 isoform disrupts Na+ interaction at the third Na+ site. <span><span class="ref-journal">J Biol Chem. </span>2010;<span class="ref-vol">285</span>:26245–54.</span> [<a href="/pmc/articles/PMC2924038/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2924038</span></a>] [<a href="/pubmed/20576601" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20576601</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.geyer.2006.780">Geyer HL, Bressman SB. The diagnosis of dystonia. <span><span class="ref-journal">Lancet Neurol. </span>2006;<span class="ref-vol">5</span>:780–90.</span> [<a href="/pubmed/16914406" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16914406</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.gurrieri.2016.2698">Gurrieri F, Tiziano FD, Zampino G, Neri G. Recognizable facial features in patients with alternating hemiplegia of childhood. <span><span class="ref-journal">Am J Med Genet A. </span>2016;<span class="ref-vol">170</span>:2698–705.</span> [<a href="/pubmed/27312461" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27312461</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.heimer.2015.1749">Heimer G, Sadaka Y, Israelian L, Feiglin A, Ruggieri A, Marshall CR, Scherer SW, Ganelin-Cohen E, Marek-Yagel D, Tzadok M, Nissenkorn A, Anikster Y, Minassian BA, Zeev BB. CAOS-episodic cerebellar ataxia, areflexia, optic atrophy, and sensorineural hearing loss: a third allelic disorder of the ATP1A3 gene. <span><span class="ref-journal">J Child Neurol. </span>2015;<span class="ref-vol">30</span>:1749–56.</span> [<a href="/pubmed/25895915" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25895915</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.heinzen.2014.503">Heinzen EL, Arzimanoglou A, Brashear A, Clapcote SJ, Gurrieri F, Goldstein DB, J&#x000f3;hannesson SH, Mikati MA, Neville B, Nicole S, Ozelius LJ, Poulsen H, Schyns T, Sweadner KJ, van den Maagdenberg A, Vilsen B, et al.  Distinct neurological disorders with ATP1A3 mutations. <span><span class="ref-journal">Lancet Neurol. </span>2014;<span class="ref-vol">13</span>:503–14.</span> [<a href="/pmc/articles/PMC4238309/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4238309</span></a>] [<a href="/pubmed/24739246" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24739246</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.heinzen.2012.1030">Heinzen EL, Swoboda KJ, Hitomi Y, Gurrieri F, Nicole S, de Vries B, Tiziano FD, Fontaine B, Walley NM, Heavin S, et al.  De novo mutations in ATP1A3 cause alternating hemiplegia of childhood. <span><span class="ref-journal">Nat Genet. </span>2012;<span class="ref-vol">44</span>:1030–4.</span> [<a href="/pmc/articles/PMC3442240/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3442240</span></a>] [<a href="/pubmed/22842232" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22842232</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.hully.2017.23">Hully M, Ropars J, Hubert L, Boddaert N, Rio M, Bernardelli M, Desguerre I, Cormier-Daire V, Munnich A, de Lonlay P, Reilly L, Besmond C, Bahi-Buisson N. Mosaicism in ATP1A3-related disorders: not just a theoretical risk. <span><span class="ref-journal">Neurogenetics. </span>2017;<span class="ref-vol">18</span>:23–8.</span> [<a href="/pubmed/27726050" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27726050</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.jaffer.2015.2859">Jaffer F, Avbersek A, Vavassori R, Fons C, Campistol J, Stagnaro M, De Grandis E, Veneselli E, Rosewich H, Gianotta M, Zucca C, Ragona F, Granata T, Nardocci N, Mikati M, Helseth AR, Boelman C, Minassian BA, Johns S, Garry SI, Scheffer IE, Gourfinkel-An I, Carrilho I, Aylett SE, Parton M, Hanna MG, Houlden H, Neville B, Kurian MA, Novy J, Sander JW, Lambiase PD, Behr ER, Schyns T, Arzimanoglou A, Cross JH, Kaski JP, Sisodiya SM. Faulty cardiac repolarization reserve in alternating hemiplegia of childhood broadens the phenotype. <span><span class="ref-journal">Brain. </span>2015;<span class="ref-vol">138</span>(Pt 10):2859–74.</span> [<a href="/pmc/articles/PMC4671482/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4671482</span></a>] [<a href="/pubmed/26297560" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26297560</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.jaffer.2017.e145">Jaffer F, Fawcett K, Sims D, Heger A, Houlden H, Hanna MG, Kingston H, Sisodiya SM. Familial childhood-onset progressive cerebellar syndrome associated with the ATP1A3 mutation. <span><span class="ref-journal">Neurol Genet. </span>2017;<span class="ref-vol">3</span>:e145.</span> [<a href="/pmc/articles/PMC5367920/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5367920</span></a>] [<a href="/pubmed/28382329" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28382329</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.jen.2007.523">Jen JC, Klein A, Boltshauser E, Cartwright MS, Roach ES, Mamsa H, Baloh RW. Prolonged hemiplegic episodes in children due to mutations in ATP1A2. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2007;<span class="ref-vol">78</span>:523–6.</span> [<a href="/pmc/articles/PMC2117823/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2117823</span></a>] [<a href="/pubmed/17435187" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17435187</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.jen.2005.529">Jen JC, Wan J, Palos TP, Howard BD, Baloh RW. Mutation in the glutamate transporter EAAT1 causes episodic ataxia, hemiplegia, and seizures. <span><span class="ref-journal">Neurology. </span>2005;<span class="ref-vol">65</span>:529–34.</span> [<a href="/pubmed/16116111" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16116111</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.jiang.2006.229">Jiang W, Chi Z, Ma L, Du B, Shang W, Guo H, Wu W. Topiramate: a new agent for patients with alternating hemiplegia of childhood. <span><span class="ref-journal">Neuropediatrics. </span>2006;<span class="ref-vol">37</span>:229–33.</span> [<a href="/pubmed/17177149" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17177149</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.kabakci.2005.860">Kabakci K, Isbruch K, Schilling K, Hedrich K, de Carvalho Aguiar P, Ozelius LJ, Kramer PL, Schwarz MH, Klein C. Genetic heterogeneity in rapid onset dystonia-parkinsonism: description of a new family. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2005;<span class="ref-vol">76</span>:860–2.</span> [<a href="/pmc/articles/PMC1739687/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1739687</span></a>] [<a href="/pubmed/15897512" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15897512</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.kamm.2008.1501">Kamm C, Fogel W, W&#x000e4;chter T, Schweitzer K, Berg D, Kruger R, Freudenstein D, Gasser T. Novel ATP1A3 mutation in a sporadic RDP patient with minimal benefit from deep brain stimulation. <span><span class="ref-journal">Neurology. </span>2008;<span class="ref-vol">70</span>:1501–3.</span> [<a href="/pubmed/18413579" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18413579</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.kansagra.2013.821">Kansagra S, Mikati MA, Vigevano F. Alternating hemiplegia of childhood. <span><span class="ref-journal">Handb Clin Neurol. </span>2013;<span class="ref-vol">112</span>:821–6.</span> [<a href="/pubmed/23622289" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23622289</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.kaunisto.2004.141">Kaunisto MA, Harno H, Vanmolkot KR, Gargus JJ, Sun G, Hamalainen E, Liukkonen E, Kallela M, van den Maagdenberg AM, Frants RR, Farkkila M, Palotie A, Wessman M. A novel missense ATP1A2 mutation in a Finnish family with familial hemiplegic migraine type 2. <span><span class="ref-journal">Neurogenetics. </span>2004;<span class="ref-vol">5</span>:141–6.</span> [<a href="/pubmed/15133718" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15133718</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.kim.2013.440">Kim DW, Lim BC, Kim KJ, Chae JH, Lee R, Lee SK. Low incidence of SCN1A genetic mutation in patients with hemiconvulsion-hemiplegia-epilepsy syndrome. <span><span class="ref-journal">Epilepsy Res. </span>2013;<span class="ref-vol">106</span>:440–5.</span> [<a href="/pubmed/23916143" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23916143</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.kramer.1999.176">Kramer PL, Mineta M, Klein C, Schilling K, de Leon D, Farlow MR, Breakefield XO, Bressman SB, Dobyns WB, Ozelius LJ, Brashear A. Rapid-onset dystonia-parkinsonism: linkage to chromosome 19q13. <span><span class="ref-journal">Ann Neurol. </span>1999;<span class="ref-vol">46</span>:176–82.</span> [<a href="/pubmed/10443882" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10443882</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.lee.2007.1808">Lee JY, Gollamudi S, Ozelius LJ, Kim JY, Jeon BS. ATP1A3 mutation in the first Asian case of rapid-onset dystonia-parkinsonism. <span><span class="ref-journal">Mov Disord. </span>2007;<span class="ref-vol">22</span>:1808–9.</span> [<a href="/pubmed/17595045" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17595045</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.maas.2016.71">Maas RP, Schieving JH, Schouten M, Kamsteeg EJ, van de Warrenburg BP. The genetic homogeneity of CAPOS syndrome: four new patients with the c.2452G&#x0003e;A (p.Glu818Lys) mutation in the ATP1A3 gene. <span><span class="ref-journal">Pediatr Neurol. </span>2016;<span class="ref-vol">59</span>:71–5.e1.</span> [<a href="/pubmed/27091223" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27091223</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.mcgrail.1991.381">McGrail KM, Phillips JM, Sweadner KJ. Immunofluorescent localization of three Na,K-ATPase isozymes in the rat central nervous system: both neurons and glia can express more than one Na,K-ATPase. <span><span class="ref-journal">J Neurosci. </span>1991;<span class="ref-vol">11</span>:381–91.</span> [<a href="/pmc/articles/PMC6575210/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6575210</span></a>] [<a href="/pubmed/1846906" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1846906</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.mckeon.2007.1325">McKeon A, Ozelius LJ, Hardiman O, Greenway MJ, Pittock SJ. Heterogeneity of presentation and outcome in the Irish rapid-onset dystonia-Parkinsonism kindred. <span><span class="ref-journal">Mov Disord. </span>2007;<span class="ref-vol">22</span>:1325–7.</span> [<a href="/pubmed/17516473" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17516473</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.moseley.2003.5317">Moseley AE, Lieske SP, Wetzel RK, James PF, He S, Shelly DA, Paul RJ, Boivin GP, Witte DP, Ramirez JM, Sweadner KJ, Lingrel JB. The Na,K-ATPase alpha 2 isoform is expressed in neurons, and its absence disrupts neuronal activity in newborn mice. <span><span class="ref-journal">J Biol Chem. </span>2003;<span class="ref-vol">278</span>:5317–24.</span> [<a href="/pubmed/12458206" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12458206</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.nicolaides.1996.419">Nicolaides P, Appleton RE, Fryer A. Cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss (CAPOS): a new syndrome. <span><span class="ref-journal">J Med Genet. </span>1996;<span class="ref-vol">33</span>:419–21.</span> [<a href="/pmc/articles/PMC1050615/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1050615</span></a>] [<a href="/pubmed/8733056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8733056</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.nygaard.1994.236">Nygaard TG, Waran SP, Levine RA, Naini AB, Chutorian AM. Dopa-responsive dystonia simulating cerebral palsy. <span><span class="ref-journal">Pediatr. Neurol. </span>1994;<span class="ref-vol">11</span>:236–40.</span> [<a href="/pubmed/7880338" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7880338</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.oblak.2014.81">Oblak AL, Hagen MC, Sweadner KJ, Haq I, Whitlow CT, Maldjian JA, Epperson F, Cook JF, Stacy M, Murrell JR, Ozelius LJ, Brashear A, Ghetti B. Rapid-onset dystonia-parkinsonism associated with the I758S mutation of the ATP1A3 gene: a neuropathologic and neuroanatomical study of four siblings. <span><span class="ref-journal">Acta Neuropathol. </span>2014;<span class="ref-vol">128</span>:81–98.</span> [<a href="/pmc/articles/PMC4059967/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4059967</span></a>] [<a href="/pubmed/24803225" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24803225</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.paciorkowski.2015.422">Paciorkowski AR, McDaniel SS, Jansen LA, Tully H, Tuttle E, Ghoneim DH, Tupal S, Gunter SA, Vasta V, Zhang Q, Tran T, Liu YB, Ozelius LJ, Brashear A, Sweadner KJ, Dobyns WB, Hahn S. Novel mutations in ATP1A3 associated with catastrophic early life epilepsy, episodic prolonged apnea, and postnatal microcephaly. <span><span class="ref-journal">Epilepsia. </span>2015;<span class="ref-vol">56</span>:422–30.</span> [<a href="/pmc/articles/PMC4363281/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4363281</span></a>] [<a href="/pubmed/25656163" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25656163</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.panagiotakaki.2010.3598">Panagiotakaki E, Gobbi G, Neville B, Ebinger F, Campistol J, Nevs&#x000ed;malov&#x000e1; S, Laan L, Casaer P, Spiel G, Giannotta M, Fons C, Ninan M, Sange G, Schyns T, Vavassori R, Poncelin D, Arzimanoglou A, et al.  Evidence of a non-progressive course of alternating hemiplegia of childhood: study of a large cohort of children and adults. <span><span class="ref-journal">Brain. </span>2010;<span class="ref-vol">133</span>:3598–610.</span> [<a href="/pubmed/20974617" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20974617</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.panagiotakaki.2015.123">Panagiotakaki E, De Grandis E, Stagnaro M, Heinzen EL, Fons C, Sisodiya S, de Vries B, Goubau C, Weckhuysen S, Kemlink D, Scheffer I, Lesca G, Rabilloud M, Klich A, Ramirez-Camacho A, Ulate-Campos A, Campistol J, Giannotta M, Moutard ML, Doummar D, Hubsch-Bonneaud C, Jaffer F, Cross H, Gurrieri F, Tiziano D, Nevsimalova S, Nicole S, Neville B, van den Maagdenberg AM, Mikati M, Goldstein DB, Vavassori R, Arzimanoglou A, et al.  Clinical profile of patients with ATP1A3 mutations in alternating hemiplegia of childhood-a study of 155 patients. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2015;<span class="ref-vol">10</span>:123.</span> [<a href="/pmc/articles/PMC4583741/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4583741</span></a>] [<a href="/pubmed/26410222" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26410222</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.pereira.2015.398">Pereira P, Guerreiro A, Fonseca M, Halpern C, Pinto-Basto J, Monteiro JP. A distinct phenotype in a novel ATP1A3 mutation: connecting the two ends of a spectrum. <span><span class="ref-journal">Mov Disord Clin Pract. </span>2015;<span class="ref-vol">3</span>:398–401.</span> [<a href="/pmc/articles/PMC6353589/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6353589</span></a>] [<a href="/pubmed/30713930" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30713930</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.pisciotta.2017.521">Pisciotta L, Gherzi M, Stagnaro M, Calevo MG, Giannotta M, Vavassori MR, Veneselli E, De Grandis E, et al.  Alternating hemiplegia of childhood: pharmacological treatment of 30 Italian patients. <span><span class="ref-journal">Brain Dev. </span>2017;<span class="ref-vol">39</span>:521–8.</span> [<a href="/pubmed/28249736" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28249736</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.potic.2015.453">Potic A, Nmezi B, Padiath QS. CAPOS syndrome and hemiplegic migraine in a novel pedigree with the specific ATP1A3 mutation. <span><span class="ref-journal">J Neurol Sci. </span>2015;<span class="ref-vol">358</span>:453–6.</span> [<a href="/pubmed/26453127" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26453127</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.rodacker.2006.18539">Rodacker V, Toustrup-Jensen M, Vilsen B. Mutations Phe785Leu and Thr618Met in Na+,K+-ATPase, associated with familial rapid-onset dystonia parkinsonism, interfere with Na+ interaction by distinct mechanisms. <span><span class="ref-journal">J Biol Chem. </span>2006;<span class="ref-vol">281</span>:18539–48.</span> [<a href="/pubmed/16632466" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16632466</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.rosewich.2014a.133">Rosewich H, Baethmann M, Ohlenbusch A, G&#x000e4;rtner J, Brockmann K. A novel ATP1A3 mutation with unique clinical presentation. <span><span class="ref-journal">J Neurol Sci. </span>2014a;<span class="ref-vol">341</span>:133–5.</span> [<a href="/pubmed/24713507" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24713507</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.rosewich.2014b.945">Rosewich H, Ohlenbusch A, Huppke P, Schlotawa L, Baethmann M, Carrilho I, Fiori S, Louren&#x000e7;o CM, Sawyer S, Steinfeld R, G&#x000e4;rtner J, Brockmann K. The expanding clinical and genetic spectrum of ATP1A3-related disorder. <span><span class="ref-journal">Neurology. </span>2014b;<span class="ref-vol">82</span>:945–55.</span> [<a href="/pubmed/24523486" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24523486</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.rosewich.2014c.861">Rosewich H, Weise D, Ohlenbusch A, G&#x000e4;rtner J, Brockmann K. Phenotypic overlap of alternating hemiplegia of childhood and CAPOS syndrome. <span><span class="ref-journal">Neurology. </span>2014c;<span class="ref-vol">83</span>:861–3.</span> [<a href="/pubmed/25056583" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25056583</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.rosewich.2017.e139">Rosewich H, Sweney MT, DeBrosse S, Ess K, Ozelius L, Andermann E, Andermann F, Andrasco G, Belgrade A, Brashear A, Ciccodicola S, Egan L, George AL Jr, Lewelt A, Magelby J, Merida M, Newcomb T, Platt V, Poncelin D, Reyna S, Sasaki M, Sotero de Menezes M, Sweadner K, Viollet L, Zupanc M, Silver K, Swoboda K. Research conference summary from the 2014 International Task Force on ATP1A3-Related Disorders. <span><span class="ref-journal">Neurol Genet. </span>2017;<span class="ref-vol">3</span>:e139.</span> [<a href="/pmc/articles/PMC5335249/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5335249</span></a>] [<a href="/pubmed/28293679" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28293679</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.roubergue.2015.7">Roubergue A, Philibert B, Gautier A, Kuster A, Markowicz K, de Villemeur TB, Vuillaumier-Barrot S, Nicole S, Roze E, Doummar D. Excellent response to a ketogenic diet in a patient with alternating hemiplegia of childhood. <span><span class="ref-journal">JIMD Rep. </span>2015;<span class="ref-vol">15</span>:7–12.</span> [<a href="/pmc/articles/PMC4270868/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4270868</span></a>] [<a href="/pubmed/24532324" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24532324</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.roubergue.2013.1457">Roubergue A, Roze E, Vuillaumier-Barrot S, Fontenille MJ, M&#x000e9;neret A, Vidailhet M, Fontaine B, Doummar D, Philibert B, Riant F, Nicole S. The multiple faces of the ATP1A3-related dystonic movement disorder. <span><span class="ref-journal">Mov Disord. </span>2013;<span class="ref-vol">28</span>:1457–9.</span> [<a href="/pubmed/23483595" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23483595</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.sasaki.2001.303">Sasaki M. Long-term effect of flunarizine on patients with alternating hemiplegia of childhood in Japan. <span><span class="ref-journal">Brain Dev. </span>2001;<span class="ref-vol">23</span>:303–5.</span> [<a href="/pubmed/11504600" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11504600</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.sasaki.2014a.153">Sasaki M, Ishii A, Saito Y, Hirose S. Intermediate form between alternating hemiplegia of childhood and rapid-onset dystonia-parkinsonism. <span><span class="ref-journal">Mov Disord. </span>2014a;<span class="ref-vol">29</span>:153–4.</span> [<a href="/pubmed/24123283" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24123283</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.sasaki.2014b.482">Sasaki M, Ishii A, Saito Y, Morisada N, Iijima K, Takada S, Araki A, Tanabe Y, Arai H, Yamashita S, Ohashi T, Oda Y, Ichiseki H, Hirabayashi S, Yasuhara A, Kawawaki H, Kimura S, Shimono M, Narumiya S, Suzuki M, Yoshida T, Oyazato Y, Tsuneishi S, Ozasa S, Yokochi K, Dejima S, Akiyama T, Kishi N, Kira R, Ikeda T, Oguni H, Zhang B, Tsuji S, Hirose S. Genotype-phenotype correlations in alternating hemiplegia of childhood. <span><span class="ref-journal">Neurology. </span>2014b;<span class="ref-vol">82</span>:482–90.</span> [<a href="/pubmed/24431296" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24431296</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.silver.1993.36">Silver K, Andermann F. Alternating hemiplegia of childhood: a study of 10 patients and results of flunarizine treatment. <span><span class="ref-journal">Neurology. </span>1993;<span class="ref-vol">43</span>:36–41.</span> [<a href="/pubmed/8423908" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8423908</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.smedemarkmargulies.2016.a001008">Smedemark-Margulies N, Brownstein CA, Vargas S, Tembulkar SK, Towne MC, Shi J, Gonzalez-Cuevas E, Liu KX, Bilguvar K, Kleiman RJ, Han MJ, Torres A, Berry GT, Yu TW, Beggs AH, Agrawal PB, Gonzalez-Heydrich J. A novel de novo mutation in ATP1A3 and childhood-onset schizophrenia. <span><span class="ref-journal">Cold Spring Harb Mol Case Stud. </span>2016;<span class="ref-vol">2</span>:a001008.</span> [<a href="/pmc/articles/PMC5002930/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5002930</span></a>] [<a href="/pubmed/27626066" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27626066</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.sweadner.2016.e0151429">Sweadner KJ, Toro C, Whitlow CT, Snively BM, Cook JF, Ozelius LJ, Markello TC, Brashear A. ATP1A3 mutation in adult rapid-onset ataxia. <span><span class="ref-journal">PLoS One. </span>2016;<span class="ref-vol">11</span>:e0151429.</span> [<a href="/pmc/articles/PMC4798776/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4798776</span></a>] [<a href="/pubmed/26990090" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26990090</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.svetel.2010.472">Svetel M, Ozelius LJ, Buckley A, Lohmann K, Brajkovi&#x00107; L, Klein C, Kosti&#x00107; VS. Rapid-onset dystonia-parkinsonism: case report. <span><span class="ref-journal">J Neurol. </span>2010;<span class="ref-vol">257</span>:472–4.</span> [<a href="/pubmed/19936820" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19936820</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.sweney.2009.e534">Sweney MT, Silver K, Gerard-Blanluet M, Pedespan JM, Renault F, Arzimanoglou A, Schlesinger-Massart M, Lewelt AJ, Reyna SP, Swoboda KJ. Alternating hemiplegia of childhood: early characteristics and evolution of a neurodevelopmental syndrome. <span><span class="ref-journal">Pediatrics. </span>2009;<span class="ref-vol">123</span>:e534–41.</span> [<a href="/pubmed/19254988" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19254988</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.swoboda.2004.884">Swoboda KJ, Kanavakis E, Xaidara A, Johnson JE, Leppert MF, Schlesinger-Massart MB, Ptacek LJ, Silver K, Youroukos S. Alternating hemiplegia of childhood or familial hemiplegic migraine? A novel ATP1A2 mutation. <span><span class="ref-journal">Ann Neurol. </span>2004;<span class="ref-vol">55</span>:884–7.</span> [<a href="/pubmed/15174025" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15174025</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.tarsy.2010.2213">Tarsy D, Sweadner KJ, Song PC. Case records of the Massachusetts General Hospital. Case 17-2010 - A 29-year-old woman with flexion of the left hand and foot and difficulty speaking. <span><span class="ref-journal">N Engl J Med. </span>2010;<span class="ref-vol">362</span>:2213–9.</span> [<a href="/pubmed/20558373" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20558373</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.termsarasab.2015.336">Termsarasab P, Yang AC, Frucht SJ. Intermediate phenotypes of ATP1A3 mutations: phenotype-genotype correlations. <span><span class="ref-journal">Tremor Other Hyperkinet Mov (N Y). </span>2015;<span class="ref-vol">5</span>:336.</span> [<a href="/pmc/articles/PMC4578012/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4578012</span></a>] [<a href="/pubmed/26417536" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26417536</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.todt.2005.315">Todt U, Dichgans M, Jurkat-Rott K, Heinze A, Zifarelli G, Koenderink JB, Goebel I, Zumbroich V, Stiller A, Ramirez A, Friedrich T, Gobel H, Kubisch C. Rare missense variants in ATP1A2 in families with clustering of common forms of migraine. <span><span class="ref-journal">Hum Mutat. </span>2005;<span class="ref-vol">26</span>:315–21.</span> [<a href="/pubmed/16110494" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16110494</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.ulatecampos.2014.377">Ulate-Campos A, Fons C, Artuch R, Castej&#x000f3;n E, Martorell L, Ozelius L, Pascual J, Campistol J. Alternating hemiplegia of childhood with a de novo mutation in ATP1A3 and changes in SLC2A1 to a ketogenic diet. <span><span class="ref-journal">Pediatr Neurol. </span>2014;2014;<span class="ref-vol">50</span>:377–9.</span> [<a href="/pubmed/24491413" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24491413</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.vanmolkot.2003.360">Vanmolkot KR, Kors EE, Hottenga JJ, Terwindt GM, Haan J, Hoefnagels WA, Black DF, Sandkuijl LA, Frants RR, Ferrari MD, van den Maagdenberg AM. Novel mutations in the Na+, K+-ATPase pump gene ATP1A2 associated with familial hemiplegic migraine and benign familial infantile convulsions. <span><span class="ref-journal">Ann Neurol. </span>2003;<span class="ref-vol">54</span>:360–6.</span> [<a href="/pubmed/12953268" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12953268</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.vilapueyo.2014.37">Vila-Pueyo M, Pons R, Raspall-Chaure M, Marc&#x000e9;-Grau A, Carre&#x000f1;o O, Sintas C, Cormand B, Pineda-Marf&#x000e0; M, Macaya A. Clinical and genetic analysis in alternating hemiplegia of childhood: ten new patients from Southern Europe. <span><span class="ref-journal">J Neurol Sci. </span>2014;<span class="ref-vol">344</span>:37–42.</span> [<a href="/pubmed/24996492" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24996492</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.viollet.2015.e0127045">Viollet L, Glusman G, Murphy KJ, Newcomb TM, Reyna SP, Sweney M, Nelson B, Andermann F, Andermann E, Acsadi G, Barbano RL, Brown C, Brunkow ME, Chugani HT, Cheyette SR, Collins A, DeBrosse SD, Galas D, Friedman J, Hood L, Huff C, Jorde LB, King MD, LaSalle B, Leventer RJ, Lewelt AJ, Massart MB, M&#x000e9;rida MR 2nd, Pt&#x000e1;&#x0010d;ek LJ, Roach JC, Rust RS, Renault F, Sanger TD, Sotero de Menezes MA, Tennyson R, Uldall P, Zhang Y, Zupanc M, Xin W, Silver K, Swoboda KJ. Alternating hemiplegia of childhood: retrospective genetic study and genotype-phenotype correlations in 187 subjects from the US AHCF Registry. <span><span class="ref-journal">PLoS One. </span>2015;<span class="ref-vol">10</span>:e0127045.</span> [<a href="/pmc/articles/PMC4440742/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4440742</span></a>] [<a href="/pubmed/25996915" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25996915</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.webb.1999.171">Webb DW, Broderick A, Brashear A, Dobyns WB. Rapid onset dystonia-parkinsonism in a 14-year-old girl. <span><span class="ref-journal">Eur J Paediatr Neurol. </span>1999;<span class="ref-vol">3</span>:171–3.</span> [<a href="/pubmed/10476366" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10476366</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.weller.2014.1062">Weller CM, Pelzer N, de Vries B, L&#x000f3;pez MA, De F&#x000e0;bregues O, Pascual J, Arroyo MA, Koelewijn SC, Stam AH, Haan J, Ferrari MD, Terwindt GM, van den Maagdenberg AM. Two novel SCN1A mutations identified in families with familial hemiplegic migraine. <span><span class="ref-journal">Cephalalgia. </span>2014;<span class="ref-vol">34</span>:1062–9.</span> [<a href="/pubmed/24707016" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24707016</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.westenberger.2017.306">Westenberger A, Max C, Br&#x000fc;ggemann N, Domingo A, Gr&#x000fc;tz K, Pawlack H, Weissbach A, K&#x000fc;hn AA, Spiegler J, Lang AE, Sperner J, Fung VS, Schallner J, Gillessen-Kaesbach G, M&#x000fc;nchau A, Klein C. Alternating hemiplegia of childhood as a new presentation of adenylate cyclase 5-mutation-associated disease: a report of two cases. <span><span class="ref-journal">J Pediatr. </span>2017;<span class="ref-vol">181</span>:306–8.e1.</span> [<a href="/pubmed/27931826" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27931826</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.yang.2014.e97274">Yang X, Gao H, Zhang J, Xu X, Liu X, Wu X, Wei L, Zhang Y. ATP1A3 mutations and genotype-phenotype correlation of alternating hemiplegia of childhood in Chinese patients. <span><span class="ref-journal">PLoS One. </span>2014;<span class="ref-vol">9</span>:e97274.</span> [<a href="/pmc/articles/PMC4026576/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4026576</span></a>] [<a href="/pubmed/24842602" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24842602</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.yano.2017.101">Yano ST, Silver K, Young R, DeBrosse SD, Ebel RS, Swoboda KJ, Acsadi G. Fever-induced paroxysmal weakness and encephalopathy, a new phenotype of ATP1A3 mutation. <span><span class="ref-journal">Pediatr Neurol. </span>2017;<span class="ref-vol">73</span>:101–5.</span> [<a href="/pubmed/28647130" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28647130</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rapid-odp.REF.zanottifregonara.2008.148">Zanotti-Fregonara P, Vidailhet M, Kas A, Ozelius LJ, Clot F, Hindi&#x000e9; E, Ravasi L, Devaux JY, Roze E. [123I]-FP-CIT and [99mTc]-HMPAO single photon emission computed tomography in a new sporadic case of rapid-onset dystonia-parkinsonism. <span><span class="ref-journal">J Neurol Sci. </span>2008;<span class="ref-vol">273</span>:148–51.</span> [<a href="/pubmed/18675996" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18675996</span></a>]</div></li></ul></div></div><div id="rapid-odp.Chapter_Notes"><h2 id="_rapid-odp_Chapter_Notes_">Chapter Notes</h2><div id="rapid-odp.Author_Notes"><h3>Author Notes</h3><p><a href="https://www.wakehealth.edu/Research/Neurology/Rapid-Onset-Dystonia-Parkinsonism.htm" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Wake Forest School of Medicine: Rapid-Onset Dystonia-Parkinsonism</a></p><p>To obtain up-to-date help, a report of possible diagnosis should be made to one of the AHC or RDP organizations listed in <a href="#rapid-odp.Resources">Resources</a>. There, contacts with experienced clinicians can be found as well as information about known pathogenic variants, and novel pathogenic variants can be considered. For AHC, parent organizations in several countries provide advice and support, raise funding for research, and hold family meetings.</p><p>Novel variants and novel symptoms associated with <i>ATP1A3</i> variants should also be reported to these organizations. The identification of non-pathogenic genetic variants is also possible in patients with other disease etiologies, and is important to arrive at a correct diagnosis. Equally important are reports of patients with typical manifestations but without a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>ATP1A3</i>, who might have a pathogenic variant in a second causative <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div><div id="rapid-odp.Acknowledgments"><h3>Acknowledgments</h3><p>The authors would like to thank Dr William B Dobyns for his contributions to this research and all of the families and patients who participated in this research.</p></div><div id="rapid-odp.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>22 February 2018 (ma) Comprehensive update posted live</div></li><li class="half_rhythm"><div>6 November 2014 (me) Comprehensive update posted live; title changed</div></li><li class="half_rhythm"><div>13 September 2012 (ab/tb) Revision: alternating hemiplegia of childhood added as a genetically related disorder</div></li><li class="half_rhythm"><div>25 August 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>19 March 2009 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> available clinically</div></li><li class="half_rhythm"><div>7 February 2008 (me) Review posted live</div></li><li class="half_rhythm"><div>5 October 2007 (ab) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1115</span><span class="label">PMID: <a href="/pubmed/20301294" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301294</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/asah1/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/cutis-laxa/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1115&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1115/?report=reader">PubReader</a></li><li><a href="/books/NBK1115/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1115" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1115" style="display:none" title="Cite this Page"><div class="bk_tt">Brashear A, Sweadner KJ, Cook JF, et al. ATP1A3-Related Neurologic Disorders. 2008 Feb 7 [Updated 2018 Feb 22]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1115/pdf/Bookshelf_NBK1115.pdf">PDF version of this page</a> (545K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#rapid-odp.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#rapid-odp.GeneReview_Scope" ref="log$=inpage&amp;link_id=inpage"><i>GeneReview</i> Scope</a></li><li><a href="#rapid-odp.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#rapid-odp.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#rapid-odp.Genetically_Related_Allelic_Di" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#rapid-odp.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#rapid-odp.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#rapid-odp.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#rapid-odp.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#rapid-odp.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#rapid-odp.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#rapid-odp.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=478[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">ATP1A3</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK1115+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1497696" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1497696" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1497696" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1497696" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25447930" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> The expanding spectrum of neurological phenotypes in children with ATP1A3 mutations, Alternating Hemiplegia of Childhood, Rapid-onset Dystonia-Parkinsonism, CAPOS and beyond.</a><span class="source">[Pediatr Neurol. 2015]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> The expanding spectrum of neurological phenotypes in children with ATP1A3 mutations, Alternating Hemiplegia of Childhood, Rapid-onset Dystonia-Parkinsonism, CAPOS and beyond.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sweney MT, Newcomb TM, Swoboda KJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Pediatr Neurol. 2015 Jan; 52(1):56-64. Epub 2014 Oct 13.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301603" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Glucose Transporter Type 1 Deficiency Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Glucose Transporter Type 1 Deficiency Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Wang D, Pascual JM, De Vivo D. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26417536" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Intermediate Phenotypes of ATP1A3 Mutations: Phenotype-Genotype Correlations.</a><span class="source">[Tremor Other Hyperkinet Mov (N...]</span><div class="brieflinkpop offscreen_noflow">Intermediate Phenotypes of ATP1A3 Mutations: Phenotype-Genotype Correlations.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Termsarasab P, Yang AC, Frucht SJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Tremor Other Hyperkinet Mov (N Y). 2015; 5:336. Epub 2015 Sep 16.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/27726050" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Mosaicism in ATP1A3-related disorders: not just a theoretical risk.</a><span class="source">[Neurogenetics. 2017]</span><div class="brieflinkpop offscreen_noflow">Mosaicism in ATP1A3-related disorders: not just a theoretical risk.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Hully M, Ropars J, Hubert L, Boddaert N, Rio M, Bernardelli M, Desguerre I, Cormier-Daire V, Munnich A, de Lonlay P, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Neurogenetics. 2017 Jan; 18(1):23-28. Epub 2016 Oct 10.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/27634470" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedarticles&amp;logdbfrom=pubmed">De novo p.Arg756Cys mutation of ATP1A3 causes an atypical form of alternating hemiplegia of childhood with prolonged paralysis and choreoathetosis.</a><span class="source">[BMC Neurol. 2016]</span><div class="brieflinkpop offscreen_noflow">De novo p.Arg756Cys mutation of ATP1A3 causes an atypical form of alternating hemiplegia of childhood with prolonged paralysis and choreoathetosis.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kanemasa H, Fukai R, Sakai Y, Torio M, Miyake N, Lee S, Ono H, Akamine S, Nishiyama K, Sanefuji M, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">BMC Neurol. 2016 Sep 15; 16:174. Epub 2016 Sep 15.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301294" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301294" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e040cbf75f66d18aa8c06ac">ATP1A3-Related Neurologic Disorders - GeneReviews®</a><div class="ralinkpop offscreen_noflow">ATP1A3-Related Neurologic Disorders - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:28:31-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal103&amp;ncbi_phid=CE8A91FEE03F0E510000000009EC0393&amp;ncbi_session=CE8A91FEE040CBE1_2540SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1115%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1115&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1115/&amp;ncbi_pagename=ATP1A3-Related Neurologic Disorders - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8A91FEE040CBE1_2540SID /projects/books/PBooks@5.22 portal103 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>